

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

**1 Comparative analysis of volatile organic compounds of breath and urine for
2 distinguishing patients with liver cirrhosis from healthy controls by using
3 electronic nose and voltammetric electronic tongue**

4 Omar Zaim^{a,b}, Alassane Diouf^{a,b}, Nezha El Bari^b, Naoual Lagdali^c, Imane
5 Benelbarhdadi^e, Fatima Zohra Ajana^c, Eduard Llobet^d and Benachir Bouchikhi^{a,*}

6 ^aSensor Electronic & Instrumentation Group, Department of Physics, Faculty of
7 Sciences, Moulay Ismaïl University of Meknes, B.P. 11201, Zitoune, Meknes,
8 Morocco.

9 ^bBiosensors and Nanotechnology Group, Department of Biology, Faculty of Sciences,
10 Moulay Ismaïl University of Meknes, B.P. 11201, Zitoune, 50003 Meknes, Morocco.

11 ^cMohammed V University, Ibn Sina Hospital, Department of Medical Gastroenterology
12 C, Rabat, Morocco.

13 ^dDepartment of Electronic Engineering, Universitat Rovira i Virgili, MINOS-EMaS,
14 Microsystems and Nanotechnologies for Chemical Analysis, Avinguda Països
15 Catalans, 26, 43007 Tarragona, Spain.

16
17
18
19
20
21
22
23
24
25 * Corresponding author:
26 Postal address: B.P. 11201, Zitoune, Meknes, Morocco
27 Tel: +212 535 53 88 70; Fax: +212 535 53 68 08
28 Email: benachir.bouchikhi@gmail.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

29 **ABSTRACT**

30 Advanced stage detection of liver cirrhosis (LCi) would lead to high mortality rates in
31 patients. Therefore, accurate and non-invasive tools for its early detection are highly
32 needed using human emanations that may reflect this disease. Human breath, along with
33 urine and blood, has long been one of the three main biological media for assessing
34 human health and environmental exposure. The primary objective of this study was to
35 explore the potential of using volatile organic compounds (VOCs) assay of exhaled
36 breath and urine samples for the diagnosis of patients with LCi and healthy controls
37 (HC). For this purpose, we used a hybrid electronic nose (E-nose) combining two sensor
38 families, consisting of an array of five commercial chemical gas sensors and six
39 interdigitated chemical gas sensors based on pristine or metal-doped WO₃ nanowires
40 for sensing volatile gases in exhaled breath. A voltammetric electronic tongue (VE-
41 tongue), composed of five working electrodes, was dedicated to the analysis of urinary
42 VOCs using cyclic voltammetry as a measurement technique. 54 patients were recruited
43 for this study, comprising 22 patients with LCi, and 32 HC. The two-sensing systems
44 coupled with pattern recognition methods, namely Principal Component Analysis
45 (PCA) and Discriminant Function Analysis (DFA), were trained to classify data clusters
46 associated with the health status of the two groups. The diagnostic performances of the
47 E-nose and VE-tongue systems were studied by using the receiver operating
48 characteristic (ROC) method. The use of the E-nose or the VE-tongue separately,
49 trained with these appropriate classifiers, showed a slight overlap indicating no clear
50 discrimination between LCi patients and HC. To improve the performance of both
51 electronic sensing devices, an emerging strategy, namely a multi-sensor data fusion
52 technique, was proposed as a second aim to overcome this shortcoming. The data fusion
53 approach of the two systems, at a medium level of abstraction, has demonstrated the
54 ability to assess human health and disease status using non-invasive screening tools
55 based on exhaled breath and urinary VOC analysis. This suggests that exhaled breath
56 as well as urinary VOCs are specific to a disease state and could potentially be used as
57 diagnostic methods.

58 **Keywords:** Liver cirrhosis; volatile organic compounds; exhaled breath analysis; urine
59 analysis; electronic sensing system; data fusion.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

60 **1. Introduction**


61 Liver disease has become a major global health problem. Indeed, it is responsible
62 for the death of two million people per year worldwide. Of these, one million are due
63 to complications of cirrhosis [1,2]. This mortality is due to symptoms that are usually
64 detected at a very advanced stage and in a metastatic state [3]. Although many efforts
65 have been made in recent years, liver cirrhosis (LCi) still causes many deaths
66 worldwide. This mortality is also due to the relatively high cost of treatment in some
67 parts of the world [4-6]. Generally, patients use drugs and surgery to hope to prolong
68 their lives.

69 To counteract the progression of the disease, early detection or intervention would
70 be of great interest. This would avoid or delay clinical interventions. For this purpose,
71 the development of effective predictive methods would be of paramount importance.

72 Efforts to develop therapeutic methods are still not effective enough. There is
73 therefore a need to improve early detection methods. Early detection and accurate
74 diagnosis of the onset of the disease are the most promising approaches to accelerate
75 the healing process or significantly reduce the associated mortality.

76 Exhaled breath contains volatile organic compounds (VOCs) that may reflect
77 disease. The development of non-invasive methods to monitor the progression of
78 diseases would offer more advantages than other conventional methods [7]. Several
79 studies have even identified VOCs emitted from the breath of the affected person as
80 indicators or markers of disease [8,9]. In other words, the onset of various diseases or
81 metabolic changes is accompanied by a significant change in the concentration of
82 certain VOCs in exhaled breath [10].

83 Besides, it is known that the human body reacts to infections and the development
84 of diseases in various ways by producing biomarkers in biological fluids, which then
85 act as a mirror of the diseases. For example, the composition of urine varies according
86 to the health status of the person [11,12]. Thus, the chemical compounds in urine are
87 good indicators because they reveal the general state of the patient's body and thus make
88 it possible to diagnose certain dysfunctions or pathologies. Depending on the
89 pathology, specific VOCs emanate from the human body. They provide information on
90 the state of health of the individual. VOCs analysis would therefore be a new approach
91 to diseases monitoring. Some studies have even established a link between urinary VOC



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


92 profiles and infectious diseases [13]. These compounds in urine, whether electro-active
93 or not, have different electrochemical activities.

94 The aim is to detect the disease at an early stage so that treatment can be started
95 quickly, which could reduce the severity and mortality of the disease. Therefore, it is
96 advisable to combine the analysis of exhaled breath samples with non-invasive body
97 fluids analysis [14-16].

98 The main disadvantage of traditional diagnostic tests is the long delay before the test
99 can be performed. Furthermore, despite their efficiency, sensitivity and often
100 specificity, chromatography techniques have many drawbacks and can only be used in
101 structured laboratories. In addition, some techniques may require patient irradiation or
102 surgery and test results are not obtained immediately. A lack of reliable tests and the
103 opacity of many clinical tests of liver function (from imaging, blood sampling to liver
104 biopsy) are also noticed. Then, these negative aspects of traditional methods have paved
105 the way for the wider development of multi-sensory systems (E-Nose and VE-tongue)
106 as useful alternatives to conventional methodologies. They are simple, reliable, cost-
107 effective, fast and can be used in complex environments. In addition, they can be used
108 on site, even by unskilled personnel [17-19].

109 For this purpose, multi-sensor-based detection systems, such as electronic noses
110 and tongues, have become serious candidates in recent years. These devices are based
111 on cross-selective sensor arrays. These systems have certain advantages due to their
112 known specific characteristics [20,21]. These detection approaches are based on
113 sensor arrays that can analyse samples with different chemical signatures [22,23]. The
114 samples are classified by distinguishing these chemical signatures using chemometric
115 methods. Electronic noses and tongues can be used in many fields such as the
116 automotive industry [24], medicine and pharmaceuticals [25], military industry [26],
117 wastewater treatment [27], and agriculture [28]. The biomedical field, such as analysis
118 of human breath and urine, is the focus of this report. Recently, a number of works
119 using multi-sensor systems, so-called E-nose and tongue are devoted to LCi [29,30].

120 However, the individual use of an electronic nose or tongue only reflects one aspect
121 of the sample (smell or taste). In order to obtain more in-depth information while
122 minimising the limitation of the detection systems, the data fusion technique can be
123 used to generate a global signature associated with the sensitivity of both devices.
124 According to some literature [31-33], data fusion technique is categorised as "low
125 level", "medium level" and "high level", depending on the processing stage at which



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

126 fusion takes place. Therefore, the data fusion strategy is an effective tool for using
127 compatible measurement data from devices.

128 When using an electronic nose and tongue, several studies have exploited data
129 fusion. They include the prediction of the mixing ratio of old frying oil [34,35], the
130 classification of different samples of honey and rice [36,37], the non-destructive
131 detection of fish freshness [38], and the evaluation of tea and strawberry juice flavours
132 [39].

133 Taking all these considerations into account, the aim of this study was to use an E-
134 nose in conjunction with a VE-tongue combined with pattern recognition methods to
135 analyse exhaled breath and human urine samples from LCi patients and HC. Indeed,
136 the key clue was to merge the data from both measurement systems to improve their
137 discrimination performance when taken separately.

138 2. Materials and methods


139 2.1. Exhaled breath and urinary collection

140 A total of 54 volunteers has participated in this study including 22 patients with LCi,
141 and 32 HC. The patient samples, used in this study, are in the primary stage of disease.
142 **Table 1** illustrates the general characteristics of all studied volunteers. In this study,
143 only adult volunteers were considered. Persons who had consumed medication, drugs,
144 alcohol, tobacco, drink or food before 12 noon were automatically excluded from the
145 study.

146 In the literature there is no standard method for breath sampling [40] and there are
147 different protocols for sample analysis [41]. Tedlar® bags have been shown to have
148 acceptable sample storage properties compared to other bags made of different
149 materials [42].

150 The volunteers were asked to rinse their mouth before collecting exhaled breath
151 samples in Tedlar® bags with mouthpiece. Three breath samples were collected per
152 each volunteer. Indeed, the volunteer blows into commercial 2 L Tedlar® bags
153 (Supelco Inc., Belfonte, PA. USA) through a one-way valve. This valve prevents
154 outside air from mixing with the collected breath. Before and after each breath sample,
155 the Tedlar® bags are cleaned 3 times with synthetic air.

156 Besides, morning urine samples are collected in 25 mL vials.



1
2
3
4
5
6
7 157 An approval was issued by the Biomedical Research Ethics Committee of the
8 158 Avicenne University Hospital (Mohammed V University, Rabat, Morocco). Prior to the
9 159 collection of the samples, all the volunteers signed a consent agreement.

11 160 2.2. Electronic sensing systems

13 161 Electronic nose and tongue have been used to analyze volatile organic compounds
14 162 (VOCs) in exhaled breath and urine samples collected from patients with LC and HC,
16 163 respectively.

18 164 2.2.1. E-nose experimental set-up

19 165 **Fig. 1** shows a schematic diagram of the system developed for the analyse of exhaled
20 166 breath gas, which consists of a Tedlar[®] bag containing the samples, a micro-pump (flow
22 167 rate of 200 L/min) to transport the analyte to a sensor chamber, a USB-6212 NI module
23 168 for data acquisition and a man-machine interface for monitoring and recording the
24 169 sensor responses. The E-nose comprises:

- 26 170 • Five chemical sensors (MQ-2, MQ-3, MQ-135, MQ-137 and MQ-138)
27 171 purchased from Henan Hanwei Electronics Co, (Zhengzhou, China). The
29 172 commercial sensors and their target compounds are listed in **Table 2**.
- 31 173 • Six interdigitated gas sensors (Pristine WO₃, Pt/WO₃, Au/Pt/WO₃, Au/WO₃,
32 174 Ni/WO₃ and Fe/WO₃). These nanostructures were deposited on alumina
33 175 substrates. Tungsten hexacarbonyl (WC₆O₆) was used as a precursor for
35 176 preparing tungsten trioxide (WO₃) nanostructures, which were synthesized
36 177 according to the process described in our previous work [43]. For the analysis
38 178 of breath samples, these interdigital chemical gas sensors are used at their
39 179 optimal operating temperatures as determined in a reported study of our
40 180 laboratory [44]. During the measurement, the sensors were irradiated with
42 181 UV light at 394 nm. The optimum temperature for good sensitivity was
43 182 100°C (for pristine WO₃, Pt/WO₃, Pt/Au/WO₃), and 160°C (for Au/WO₃,
45 183 Ni/WO₃, Fe/WO₃).
- 46 184 • A relative humidity sensor (Honeywell HIH 4000-002), and a temperature
47 185 sensor (LM35DZ) from National Semiconductor.

49 186 For each volunteer, three replica breath samples were collected. They were then
50 187 transferred to the sensor chamber by pumping the analyte for 10 minutes. The responses
52 188 of the gas sensors are recorded as conductance vs. time.

53
54
55
56
57
58
59
60
61
62
63
64
65

2.2.2. VE-tongue experimental set-up

The scheme of the experimental VE-tongue used for urine samples analysis is shown in Fig. 2. It is a conventional electrochemical cell based on a three-electrode configuration. Briefly, it consists of an Ag/AgCl reference electrode and an array of five working electrodes: copper (Cu), glassy carbon (GC), platinum (Pt), palladium (Pd), gold (Au), and an auxiliary electrode made of platinum.

After explaining the measurement protocol to the volunteer, a new polystyrene bottle was given to him to get his urine sample. The VE-tongue analysis of the urine is immediately performed after the urine is received without any pre-treatment. Once the measurement is done, the urine sample is stored at -4°C .

Electrochemical measurements are carried out by immersing the electrodes in a vessel containing the sample. The measurements are then initiated, and a data acquisition device (PalmSens³ potentiostat, Netherlands) was used to automatically store the output data of the electrode responses. The CV technique was configured as follows: the potential scanning window was between -0.2 to 0.6 V. The scanning was performed at 50 mV/s. To avoid possible measurement errors due to contamination of the electrode surfaces, the electrodes were all rinsed with piranha and polished before and after each measurement. This also helps to minimize drift.

During electrochemical measurements, the electrode responses are recorded as voltammograms. For the sake of repeatability in the measurements, 6 measurement repetitions were carried out for each urine sample. The total response obtained from the analyzed analyte was therefore 6 voltammograms x 5 electrodes per urine sample.

These experiments were carried out at room temperature (25°C). After analysis of the exhaled breath and urine samples, a very large database was obtained, which made interpretation difficult. To overcome this drawback, relevant features were extracted from the responses of both systems (E-nose and VE-tongue) to facilitate visualization, interpretation and understanding.

2.3. Data pre-processing

Sensor response drift is a general issue that is considered in this work. Numerous correction techniques have been tested on pre-treatment data to reduce it [45].

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

219 Indeed, to reduce the effect of sensor drifts, normalization procedure of each gas
220 sensor response ($\frac{G-G_0}{G_0}$) is used where G is the measured conductance and G₀ is the
221 baseline [45].

222 To simplify the processing of multivariate data, only the variables of interest are
223 retained in the initial data. These variables retain as much information as possible from
224 these responses. In this study, the analysis of the responses of E-nose system was
225 carried out using the two variables cited below:

- 226 • **ΔG** = ($G_s - G_0$): The difference between the stabilised conductance (G_s)
227 and the initial conductance (G_0);
- 228 • **AUC**: Area under the response curve of the sensor measured by a trapezoidal
229 method. The area considered is between 1 and 9 minutes of the measurement
230 time.

231 Furthermore, for processing the VE-tongue database, two eigenvalues related to the
232 output current values were exacted from the cyclic voltammogram response of each
233 working electrode, including:

- 234 • **Pt_{ox}** : Maximum signal slope in the first half wave (oxidation)
- 235 • **Area**: Area under the response curve of the sensor.

236 In this study, for the E-nose, 162 breath samples (54 volunteers * 3 Tedlar bags)
237 were measured and 2 features (ΔG and AUC) were used. These 2 features were
238 extracted from the response of each gas sensor. Since we have 11 gas sensors, for each
239 breath sample, 22 features were extracted. Therefore, for all samples, we had a total of
240 3564 variables (i.e. 162 samples * 22). The same logic was used for the VE-tongue.
241 Thus, 7128 variables were extracted (i.e. 324 samples*22).

242 2.4. Data analysis

243 After extraction of the variables, data processing algorithms (PCA, DFA) are used
244 to classify the analyzed samples for better visualisation and interpretation [46].
245 Chemometric techniques are crucial tools for obtaining a practical system capable of
246 characterising a wide diversity of compounds [47].

247 The aim of using these methods in this work is to evaluate the effectiveness of the
248 E-nose and VE-tongue in discriminating between the two groups based on breath and
249 urine samples using both supervised and unsupervised methods.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

250 PCA is an unsupervised linear method that uses an orthogonal transformation to
251 reduce the dimensionality of multivariate data [48,49]. This transformation is applied
252 so that the principal components (PCs) have the greatest possible variance while
253 remaining orthogonal. In this study, PCA was used to process multivariate data from
254 the E-nose and VE-tongue to obtain a clear illustration in a low-space projection.

255 DFA is a supervised chemometric method whose effectiveness has been proven in
256 many applications of electronic sensing systems [50]. With the DFA method, the
257 discriminating functions are determined in such a way that the ratio within a group is
258 minimised (intra-class variance). At the same time, it maximises the ratio between
259 groups (inter-class variance).

260 A ROC curve is a graph that illustrates the diagnostic ability of a binary classification
261 system as a function of the variation in its discrimination threshold. The ROC curve is
262 obtained by plotting the true positive rate (TPR) against the false positive rate (FPR)
263 for different thresholds. The true positive rate is called sensitivity, recall or probability
264 of detection [51] in machine learning. The false positive rate is known as the false alarm
265 probability [51] and can be calculated as follows (1 - specificity).

266 SVM is a supervised nonlinear chemometric technique based on the notion of
267 maximum margin. The maximum margin is the distance between the separation
268 boundary and the nearest samples [52]. SVMs allows to draw a hyperplane for this
269 separation. There is a multitude of valid hyperplanes. However, SVMs searches among
270 the valid hyperplanes for the one that not only passes "in the middle" of the points of
271 the two classes but also maximizes the margin.

272 2.5. Multisensory data fusion approach

273 In this study, a data fusion strategy was adopted. The main objective of using this
274 approach was to improve the classification performance obtained using the two
275 electronic devices individually. Here, medium level data fusion was applied to
276 compensate for the limitations in terms of classification/discrimination of HC and LCi
277 patient samples by the used electronic sensing systems. In this approach, the fusion is
278 done using the features extracted from the E-nose and VE-tongue data [39,53]. It is
279 obvious that the number of features from the two systems should be similar when
280 merging data using the medium level abstraction approach. If the number of features
281 from one instrument is significantly higher, they could dominate the merged dataset. In

1
2
3
4
5
6
7 282 our case, the E-nose dataset is larger than that of the VE-tongue. For this reason, since
8 283 only 5 electrodes were used for the VE-tongue, an appropriate method of selecting the
9 284 five most discriminating gas sensors was carried out in order to obtain a similar
10 285 dimensionality of both matrices. Therefore, using the medium level abstraction
11 286 approach, the datasets obtained from each multi-sensor system (E-nose and VE-tongue)
12 287 were merged into a single matrix of 162 samples on 4 features (ΔG and area for the E-
13 288 nose; Ptox and area for the VE-tongue).

17 289 **3. Results and discussion**

18 290 3.1. Analysis of VOCs in exhaled breath by E-nose system

19 291 Sensor responses were recorded during the 10 minutes of breath exposure, followed
20 292 by 10 minutes of return to baseline under synthetic air. **Fig. 3** displays the responses of
21 293 the two families of gas sensor arrays towards exhaled breath samples of HC and LCi.
22 294 As shown in **Fig. 3**, the response of the sensor array to the exhaled breath gas was
23 295 directly related to the gas detection and pattern identification. The MQ-138 sensor of
24 296 **Fig. 3(b)** showed higher sensitivities than the other sensors. Many studies have been
25 297 performed on the analyze of breath VOC biomarkers from LCi patients and reported
26 298 that volatile biomarkers in breath associated with liver cirrhosis are Methanol [54-56],
27 299 Dimethyl sulfide [57,58], Ethanol and Toluene [58]. Though the other sensors showed
28 300 relatively low signals, there were differences between LCi patients and HC (**Fig 3(a)**).
29 301 We can notice that the gas reaction was completed after 600 s, whereas the desorption
30 302 of the gas was completed after around 30 s for MQ sensors. However, this time to return
31 303 to the baseline remains longer for interdigitated chemical gas sensors based on pristine
32 304 or metal-doped WO_3 nanowires (**Fig. 3 (c,d)**). Besides, Au/ WO_3 sensor response (**Fig**
33 305 **3(d)**) provided higher response toward LCi patient's breath sample than to the HC (**Fig**
34 306 **3(c)**). This behaviour can be justified by the difference in VOC concentrations in the
35 307 breath related to HC and LCi patients [6,23].

36 308 3.2. Analysis of urinary VOCs by VE-tongue

37 309 **Fig. 4** shows different electrochemical responses, depending on the health state
38 310 associated with the urine samples that were analysed. These irreversible responses are
39 311 different in terms of shape and amplitude. However, oxidation processes are only
40 312 observed when using Cu working electrode. This oxidation effect is more pronounced
41 313 in urine samples of patients with LCi. This is probably due to abnormal variation of
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

copper level in the body of LCi patients and released in urine [59-68]. It should be noted that the intensity of the voltammograms yield by Cu working electrode corresponding to urine samples of patients with LCi (Fig. 4(b)) is higher than those of HC (Fig. 4(a)). The oxidation peak is around 0.30 V for LCi (Fig. 4(b)), while the Cu electrode admits a small oxidation peak at around 0.02 V for the urine sample of HC (Fig. 4(a)). With the Cu electrode, the voltammograms demonstrate metal oxidation, forming copper ions in urine samples, but with different trend for LCi. According to the literature, copper primarily deposits in the liver and the lethal dose is about 10-20 g [69]. On one hand, A. Amit et al. and Y. Yoshida et al. report that liver problems modify the metabolism of trace elements. In this case, they declare the presence of either a high presence of copper or a deficiency of zinc (Zn) [63,70]. In this purpose, D. Rahelic et al. explains the role of copper in the redox process [71]. Consequently, the proposed VE-tongue provides findings that show that the state of health influences the chemical composition of the urine and corroborates the literature.

3.3. Radar plot results

The sensors are not specific to one compound. However, each sensor is sensitive to several compounds. The combination of the responses allows plotting a specific chemical signature. After the features' extraction step, the radar plot was used to see if there were any differences or similarities in terms of the chemical signatures of the various breath and urine samples from patients with LCi and HC. Fig. 5 shows the radar plot results highlighting the contribution of the E-nose gas sensors. These plots were constructed using the area value as a feature. There is a clear variation in pattern between the breath-prints of the two groups.

Fig. 6 shows the radar plots of the two sets of urine samples obtained after extraction of the relevant features from the voltammograms. Each representation has a particular chemical signature in their taste profile, although there are some similarities. The majority of the electrodes showed similar behaviour for the two groups except for Pd electrode. This could strongly influence the classification performance of the VE-tongue, thus generating an overlap in the sample patterns.

3.4. PCA discrimination results

The discrimination results of the two sensing systems individually by using PCA are depicted in Fig. 7. Using two features (ΔG and AUC), the PCA results for the E-nose (Fig. 7(a)) indicate a data variance of 61.98%, which was explained by the first three

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

347 principal components (PCs). This three-dimensional PCA plot shows a classification
348 among the breath patterns of LCi patients and HC with slight overlapping between the
349 two clusters.

350 Besides, the VE-tongue discrimination results obtained by applying PCA are shown
351 in **Fig. 7(b)**, where all three PCs contributed to a score of 81.38%. Here, the samples of
352 the LCi patients also overlapped with those of the HC. This is probably due to the
353 similarity of the electrochemical responses of the majority of the electrodes.


354 3.5. DFA discrimination results

355 The same dataset was used to perform a treatment using a supervised method, called
356 DFA. It was used to distinguish between different samples of breath and urine
357 according to their health states. The results of the DFA after its application to the
358 responses of the two systems are shown in **Fig. 8**. The same features as for the PCA
359 were used. The results in **Fig. 8(a)** show a discrimination between LCi patients and HC
360 breath samples. In contrast, the discriminatory feasibility of the VE-tongue, shown in
361 **Fig. 8(b)**, does not lead to a perfect separation between LCi and HC samples. These
362 results confirm those obtained by the PCA analysis and suggest the use of data fusion
363 to recognise the two health states.

364 3.6. Receiver operating characteristic (ROC) results

365 ROC curves for the E-nose and VE-tongue data were plotted. AUC values were
366 calculated to assess the diagnostic value of each data item. The ROC curve and AUC
367 analysis of the logistic regression were performed to explore the diagnostic
368 performances of the E-nose and VE-tongue models. **Fig. 9(a)** shows the ROC curve of
369 the E-nose data with an AUC of 0.965 corresponding to the analysis of LCi and HC
370 breath samples.

371 Besides, **Fig. 9(b)** shows the ROC curve of the VE-tongue model data with an AUC
372 of 0.950 for the distinction of urine samples corresponding to LCi and HC. These results
373 show that the diagnostic performances of two multi-sensor systems is significantly
374 significant. Furthermore, the diagnostic performance of the E-nose model is higher than
375 that of the VE-tongue model.



3.7. SVMs classification results

The dataset trained for 20 volunteers (10 LCi and 10 HC patients) of balanced age was used to run the SVMs method. It was used to distinguish between different breath and urine samples according to their health status.

Table 3 shows the SVMs results of the classification of 60 breath samples (20 volunteers providing 3 samples each). The rows of the table indicate the actual health states and the columns the predicted states. The SVMs method achieved a success rate of 98.33% in the recognition of the two groups studied (LCi and HC). As can be seen from the table, one error was detected: a sample belonging to LCi was classified in the HC group.

Besides, Table 4 presents the SVMs results when analyzing the data from the VE-tongue for 120 urine samples. The same trend as for the E-nose is observed with the occurrence of three errors and a success rate of 97.50%.

3.8. Data fusion results

3.8.1. PCA classification results

Using data fusion, the PCA method was applied to discriminate the two types of samples. Fig. 10 shows the discrimination results obtained by combining the data from the two systems, where all three principal components contributed with a score of 64.23%. Indeed, we can notice both groups are well discriminated, demonstrating the ability of the combination of two systems to overcome the overlap observed previously. The close linkage of biological emanations to health status provides a unique signature. This explains the good discrimination obtained by merging the data as opposed to separating them.

3.8.2. DFA classification results

DFA was also used to examine the ability of the data fusion technique to improve the classification of different samples according to their health status. Fig. 11 shows the first two DFA functions for the classification of HC and LCi patients using data fusion of the E-nose and VE-tongue systems. The result reveals a perfect discrimination between HC and LCi patients. Therefore, the processing of the data by the DFA technique reveals the effectiveness of the proposed data fusion method in distinguishing HC and LCi patients.

3.8.3. Receiver operating characteristic (ROC) results

A ROC analysis was also performed to evaluate the diagnostic performance after data fusion to improve the classification of different samples according to their health status. Fig. 12 shows the ROC curve corresponding to the merged data of the two devices with a very good AUC of 0.999. This result shows that the diagnostic performance of the model obtained after data fusion is superior to those found using the E-nose and VE-tongue data individually. These results confirm the effectiveness of merging data from two compatible systems to successfully distinguish HC and LCi patients.

3.8.4. SVMs classification results

~~In order to~~ To enhance the SVMs classifications obtained by taking the two measurement systems individually, SVMs was applied to the merged data. For this purpose, 20 age-balanced volunteers (10 LCi and 10 HC patients) were considered.

Table 5 shows the results of the SVMs classification for the fusion of the E-nose and VE-tongue data. A very good result by the SVMs method is achieved with a success rate of 100% for the recognition of LCi and HC volunteers. In the light of this result, it can be concluded that the data fusion technique is a good way to improve the classification of different samples.

4. Conclusion

In this work, an electronic nose and tongue were used to analyse breath and urine samples from patients with LCi and HC. With the help of pattern recognition methods, the two electronic devices, taken individually, showed limitations in terms of discrimination of the two study groups. To overcome the limitation of the individual systems, the data fusion of the E-nose and VE-tongue provided very satisfactory results in terms of discrimination and classification. Indeed, the PCA results obtained from the merged data showed a good classification of the different breath and urine samples according to their health status. In addition, the supervised method (DFA) was able to clearly differentiate between LCi patients and HC. Moreover, the diagnostic result of data fusion obtained by ROC curve is superior to those found using the E-nose and VE-tongue data individually. The advantage of this study is the proposal of electronic sensing systems as alternative tools to conventional techniques, which have many drawbacks for the analysis of this disease. This demonstrates that the two proposed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


439 devices have a classification and predictive capability that would certainly contribute
440 to facilitating the early diagnosis of diseases. In view of the results of this study, and
441 thanks to their portability and speed, they could therefore be used as non-invasive
442 diagnosis for other diseases.

443 **Declaration of Competing Interest**

444 The authors declare that they have no known competing financial interests or
445 personal relationships that could have appeared to influence the work reported in this
446 paper.

447 **Acknowledgement**

448 Authors gratefully acknowledge Moulay Ismaïl University of Meknes for financial
449 support of the project “Research support”. The authors thank and wish to express their
450 gratitude to Dr. Tarik SAIDI for the excellent technical assistance in the fabrication
451 process of WO₃ sensors.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

452 **References**

453 [1] S.K. Asrani, H. Devarbhavi, J. Eaton, P.S. Kamath, Burden of liver diseases in the
454 world, *J. Hepatol.* 70 (2019) 151–171.

455 [2] A.A. Mokdad, A.D. Lopez, S. Shahraz, R. Lozano, A.H. Mokdad, J. Stanaway, M.
456 Naghavi, Liver cirrhosis mortality in 187 countries between 1980 and 2010: a
457 systematic analysis, *BMC Med.* 12 (2014) 145.

458 [3] N. Afdhal, J. McHutchison, R. Brown, I. Jacobson, M. Manns, F. Poordad, B.
459 Weksler, R. Esteban, Thrombocytopenia associated with chronic liver disease, *J.*
460 *Hepatol.* 48 (2008) 1000–1007.

461 [4] M. Mohammadi, N. Zarghami, M. Hedayati, S. Ghaemmaghami, R.M. Yamchi, M.
462 Mohaddes, Visfatin effects on telomerase gene expression in AGS gastric cancer cell
463 line, *Indian J. Cancer* 52 (2015) 32–35.


464 [5] S. Kumar, J. Huang, N. Abbassi-Ghadi, H.A. Mackenzie, K.A. Veselkov, J.M.
465 Hoare, G.B. Hanna, Mass spectrometric analysis of exhaled breath for the identification
466 of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma,
467 *Ann. Surg.* 262 (2015) 981–990.

468 [6] K.E. Pijls, A. Smolinska, D.M. Jonkers, J.W. Dallinga, A.A. Masclee, G.H. Koek,
469 F.J. Van Schooten, A profile of volatile organic compounds in exhaled air as a potential
470 non-invasive biomarker for liver cirrhosis, *Sci. Rep.* 6 (2016) 1–8.

471 [7] C. Ghosh, V. Singh, J. Grandy, J. Pawliszyn, Recent advances in breath analysis to
472 track human health by new enrichment technologies, *J. Sep. Sci.* 43 (2020) 226–240.

473 [8] C.M. Durán-Acevedo, J.M. Cáceres-Tarazona, Low-cost desorption unit coupled
474 with a gold nanoparticles gas sensor arrays for the analysis of volatile organic
475 compounds emitted from the exhaled breath (gastric cancer and control samples),
476 *Microelectron. Eng.* 237 (2020) 111483.

477 [9] M. Rondanelli, F. Perdoni, V. Infantino, M.A. Faliva, G. Peroni, G. Iannello, M.
478 Nichetti, T.A. Alalwan, S. Perna, C. Cocuzza, Volatile organic compounds as
479 biomarkers of gastrointestinal diseases and nutritional status, *J. Anal. Methods Chem.*
480 2019 (2019) 1–15.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

481 [10] G. Lubes, M. Goodarzi, GC–MS based metabolomics used for the identification
482 of cancer volatile organic compounds as biomarkers, *J. Pharm. Biomed. Anal.* 147
483 (2018) 313–322.

484 [11] M. Shao, H. Lu, M. Yang, Y. Liu, P. Yin, G. Li, Y. Wang, L. Chen, Q. Chen, C.
485 Zhao, Q. Lu, T. Wu, G. Ji, Serum and urine metabolomics reveal potential biomarkers
486 of T2DM patients with nephropathy, *Ann. Transl. Med.* 8(5) (2020) 1–22.

487 [12] P.M. Villeneuve, S.M. Bagshaw, Assessment of urine biochemistry, In *Critical*
488 *Care Nephrology*, (2019) pp. 323–328.

489 [13] Q. Gao, W.Y. Lee, Urinary metabolites for urological cancer detection: a review
490 on the application of volatile organic compounds for cancers, *Am. J. Clin. Exp. Urol.* 7
491 (2019) 232.

492 [14] A. Krilaviciute, C. Stock, M. Leja, H. Brenner, Potential of non-invasive breath
493 tests for preselecting individuals for invasive gastric cancer screening endoscopy, *J.*
494 *Breath Res.* 12 (2018) 036009.


495 [15] S.R. Markar, J. Lagergren, G.B. Hanna, Research protocol for a diagnostic study
496 of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer,
497 *BMJ open* 6 (2016) e009139.

498 [16] L. Xu, Y.H. Qu, X.D. Chu, R. Wang, H.H. Nelson, Y.T. Gao, J.M. Yuan, Urinary
499 levels of N-nitroso compounds in relation to risk of gastric cancer: findings from the
500 shanghai cohort study, *PloS one* 10 (2015) e0117326.

501 [17] E. Turppa, I. Polaka, E. Vasiljevs, J.M. Kortelainen, G. Shani, M. Leja, H. Haick,
502 Repeatability study on a classifier for gastric cancer detection from breath sensor data,
503 In 19th IEEE International conference on bioinformatics and bioengineering (2019)
504 450–453.

505 [18] D. Hashoul, H. Haick, Sensors for detecting pulmonary diseases from exhaled
506 breath, *Eur. Respir. J.* 28 (2019) 190011.

507 [19] K. Matsumoto, Y. Murakami, Y. Shimizu, H. Takahiro, I. Wataru, I. Masatsugu,
508 Electronic nose to distinguish bladder cancer by urinary odour feature: A pilot study,
509 *Cancer Biomark.* 28 (2020) 33–39.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

510 [20] W. Hu, L. Wan, Y. Jian, C. Ren, K. Jin, X. Su, X. Bai, H. Haick, M. Yao, W. Wu,
511 Electronic noses: from advanced materials to sensors aided with data processing, *Adv.*
512 *Mater. Technol.* 4 (2019) 1800488.

513 [21] A. Diouf, M. Moufid, D. Bouyahya, L. Österlund, N. El Bari, B. Bouchikhi, An
514 electrochemical sensor based on chitosan capped with gold nanoparticles combined
515 with a voltammetric electronic tongue for quantitative aspirin detection in human
516 physiological fluids and tablets, *Mater. Sci. Eng. C* 110 (2020) 110665.

517 [22] A. De Vincentis, G. Pennazza, M. Santonico, U.V. Gentilucci, G. Galati, P. Gallo,
518 C. Vernile, C. Pedone, R.A. Incalzi, A. Picardi, Breath-print analysis by e-nose for
519 classifying and monitoring chronic liver disease: a proof-of-concept study, *Sci. Rep.* 6
520 (2016) 25337.

521 [23] K. Eng, N. Alkhouri, F. Cikach, N. Patel, C. Yan, D. Grove, R. Lopez, E. Rome,
522 R.A. Dweik, Analysis of breath volatile organic compounds in children with chronic
523 liver disease compared to healthy controls, *J. Breath Res.* 9 (2015) 026002.

524 [24] M. Morvan, T. Talou, A. Gaset, J.F. Beziau, Electronic-nose systems for control
525 quality applications in automotive industry, *Sens. Actuators B Chem.* 69(3) (2000) 384-
526 388.

527 [25] L. Zhu, R.A. Seburg, E. Tsai, S. Puech, J.C. Mifsud, Flavor analysis in a
528 pharmaceutical oral solution formulation using an electronic-nose, *J. Pharm. Biomed.*
529 *Anal.* 34(3) (2004) 453-461.

530 [26] M. Winkler, K.D. Tuchs, K. Hughes, G. Barclay, Theoretical and practical aspects
531 of military wireless sensor networks, *J. Telecommun. Inf. Technol.* (2008) 37-45.

532 [27] M.C. Martínez-Bisbal, E. Loeff, E. Olivas, N. Carbó, F.J. García-Castillo, J.
533 López-Carrero, I. Tormos, F.J. Tejadillos, J.G. Berlanga, R. Martínez-Máñez, M.
534 Alcañiz, J. Soto, A voltammetric electronic tongue for the quantitative analysis of
535 quality parameters in wastewater, *Electroanalysis* 29(4) (2017) 1147-1153.

536 [28] I.M. Apetrei, C. Apetrei, Detection of virgin olive oil adulteration using a
537 voltammetric e-tongue, *Comput. Electron. Agric.* 108 (2014) 148-154.

538 [29] A. De Vincentis, G. Pennazza, M. Santonico, U. Vespasiani-Gentilucci, G. Galati,
539 P. Gallo, A. Zompanti, C. Pedone, R.A. Incalzi, A. Picardi, Breath-print analysis by e-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

540 nose may refine risk stratification for adverse outcomes in cirrhotic patients, *Liver Inter.*
541 37(2) (2017) 242-250.

542 [30] M. Muley, U. Vespasiani-Gentilucci, A. De Vincentis, M. Santonico, G. Pennazza,
543 S. Sanguedolce, C. De Luca, F. Plotti, A. Picardi, R. Antonelli-Incalzi, Voltammetric
544 analysis for distinguishing portal hypertension-related from malignancy-related ascites:
545 A proof of concept study, *Plos one* 15(5) (2020) e0233350.

546 [31] A. Rudnitskaya, D. Kirsanov, A. Legin, K. Beullens, J. Lammertyn, B.M. Nicolaï,
547 J. Irudayaraj, Analysis of apples varieties—Comparison of electronic tongue with
548 different analytical techniques, *Sensor Actuat. B-Chem.* 116 (2006) 23–28.

549 [32] C. Di Natale, R. Paolesse, A. Macagnano, A. Mantini, A. D’Amico, A. Legin, L.
550 Lvova, A. Rudnitskaya, Y. Vlasov, Electronic nose and electronic tongue integration
551 for improved classification of clinical and food samples, *Sensor Actuat. B-Chem.* 64
552 (2000) 15–21.

553 [33] S. Roussel, V. Bellon-Maurel, J.M. Roger, P. Grenier, Fusion of aroma, FT-IR and
554 UV sensor data based on the Bayesian inference. Application to the discrimination of
555 white grape varieties, *Chemometr. Intell. Lab.* 65 (2003) 209–219.

556 [34] S. Buratti, C. Malegori, S. Benedetti, P. Oliveri, G. Giovanelli, E-nose, e-tongue
557 and e-eye for edible olive oil characterization and shelf life assessment: A powerful
558 data fusion approach, *Talanta* 182 (2018) 131–141.

559 [35] H. Men, D. Chen, X. Zhang, J. Liu, K. Ning, Data fusion of electronic nose and
560 electronic tongue for detection of mixed edible-oil, *J. Sens.* 2014 (2014) 1–7.

561 [36] A. Zakaria, A.Y. Shakaff, M.J. Masnan, M.N. Ahmad, A.H. Adom, M.N. Jaafar,
562 S.A. Ghani, A.H. Abdullah, A.H. Aziz, L.M. Kamarudin, A biomimetic sensor for the
563 classification of honeys of different floral origin and the detection of adulteration,
564 *Sensors* 11 (2010) 7799–7822.

565 [37] L. Lu, S. Deng, Z. Zhu, S. Tian, Classification of rice by combining electronic
566 tongue and nose, *Food Anal. Methods* 8 (2015) 1893–1902.

567 [38] F. Han, X. Huang, E. Teye, F. Gu, H. Gu, Nondestructive detection of fish
568 freshness during its preservation by combining electronic nose and electronic tongue
569 techniques in conjunction with chemometric analysis, *Anal. Methods* 6 (2014) 529–
570 536.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

571 [\[39\]](#) Z. Haddi, S. Mabrouk, M. Bougrini, K. Tahri, K. Sghaier, H. Barhoumi, N. El Bari,
572 A. Maaref, N. Jaffrezic-Renault, B. Bouchikhi, E-Nose and e-Tongue combination for
573 improved recognition of fruit juice samples, *Food Chem.* 150 (2014) 246–253.

574 [\[40\]](#) M. Righettoni, A. Amann, S.E. Pratsinis, Breath analysis by nanostructured metal
575 oxides as chemo-resistive gas sensors, *Mater. Today* 18(3) (2015) 163–171.

576 [\[41\]](#) O. Lawal, W.M. Ahmed, T.M. Nijsen, R. Goodacre, S.J. Fowler, Exhaled breath
577 analysis: a review of ‘breath-taking’ methods for off-line analysis, *Metabolomics*
578 13(10) (2017) 1-16.

579 [\[42\]](#) J. Beauchamp, J. Herbig, R. Gutmann, A. Hansel, On the use of Tedlar® bags for
580 breath-gas sampling and analysis, *J. Breath Res.* 2(4), (2008) 046001.

581 [\[43\]](#) T. Saidi, T.G. Welearegay, O. Zaim, O.G. León, R. Ionescu, N. El Bari, B.
582 Bouchikhi, Ability of discrimination of breath from smoker and non-smoker controls
583 by using an electronic nose based on WO₃ nanowires and SnO₂ sensors, In *IEEE*
584 *International Symposium on Olfaction and Electronic Nose (ISOEN)* (2017) 1–3.

585 [\[44\]](#) T. Saidi, D. Palmowski, S. Babicz-Kiewlicz, T.G. Welearegay, N. El Bari, R.
586 Ionescu, J. Smulko, B. Bouchikhi, Exhaled breath gas sensing using pristine and
587 functionalized WO₃ nanowire sensors enhanced by UV-light irradiation, *Sensor Actuat.*
588 *B-Chem.* 273 (2018) 1719–1729.

589 [\[45\]](#) D. Ahmadou, R. Laref, E. Losson, M. Siadat, Reduction of drift impact in gas
590 sensor response to improve quantitative odor analysis, In *IEEE International*
591 *Conference on Industrial Technology (ICIT)* (2017) 928–933.

592 [\[46\]](#) O. Zaim, T. Saidi, N. El Bari, B. Bouchikhi, Assessment of "breath print" in
593 patients with chronic kidney disease during dialysis by non-invasive breath screening
594 of exhaled volatile compounds using an electronic nose, In *IEEE International*
595 *Symposium on Olfaction and Electronic Nose (ISOEN)* (2019) 1–4.

596 [\[47\]](#) S. Dragonieri, J.T. Annema, R. Schot, M.P. van der Schee, A. Spanevello, P.
597 Carratú, O. Resta, K.F. Rabe, P.J. Sterk, An electronic nose in the discrimination of
598 patients with non-small cell lung cancer and COPD, *Lung cancer* 64 (2009)166–170.

599 [\[48\]](#) R. Bro, A.K. Smilde, Principal component analysis, *Anal. Methods* 6 (2014) 2812–
600 2831.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

601 [49] Y. Aït-Sahalia, D. Xiu, Principal component analysis of high-frequency data, *J.*
602 *Am. Stat. Assoc.* 114 (2019) 287–303.

603 [50] M. Bougrini, K. Tahri, Z. Haddi, T. Saidi, N. El Bari, B. Bouchikhi, Detection of
604 adulteration in argan oil by using an electronic nose and a voltammetric electronic
605 tongue, *J. Sensors* 2014 (2014) 1–10.

606 [51] T. Fawcett, An introduction to ROC analysis, *Pattern Recognit. Lett.* 27(8)
607 (2006) 861-874.

608 [52] N. Guenther, M. Schonlau, Support vector machines, *Stata J.* 16(4) (2016) 917-
609 937.

610 [53] J.M. Gutiérrez, Z. Haddi, A. Amari, B. Bouchikhi, A. Mimendia, X. Cetó, M. del
611 Valle, Hybrid electronic tongue based on multisensor data fusion for discrimination of
612 beers, *Sensor Actuat. B-Chem.* 177 (2013) 989–996.

613 [54] F. Morisco, E. Aprea, V. Lembo, V. Fogliano, P. Vitaglione, G. Mazzone, L.
614 Cappellin, F. Gasperi, S. Masone, G.D. De Palma, R. Marmo, N. Caporaso, F. Biasioli,
615 Rapid “Breath-Print” of liver cirrhosis by proton transfer reaction time-of-flight mass
616 spectrometry. A pilot study, *PLoS One* 8(4) (2013) e59658.

617 [55] R.F. Del Río, M.E. O'Hara, A. Holt, P. Pemberton, T. Shah, T. Whitehouse, C.A.
618 Mayhew, Volatile biomarkers in breath associated with liver cirrhosis—comparisons
619 of pre-and post-liver transplant breath samples, *EBioMedicine* 2(9) (2015) 1243-1250.

620 [56] U. Srimathi, V. Nagarajan, R. Chandiramouli, Germanane nanosheet as a novel
621 biosensor for liver cirrhosis based on adsorption of biomarker volatiles—a DFT study,
622 *Appl. Surf. Sci.* 475 (2019) 990-998.

623 [57] J. Dadamio, S. Van den Velde, W. Laleman, P. Van Hee, W. Coucke, F. Nevens,
624 M. Quirynen, Breath biomarkers of liver cirrhosis, *J. Chromatogr. B* 905 (2012) 17-22.

625 [58] A. Mashir, A.R. Tamimi TI, D. Laskowski, K.M. Paschke, D.E. Grove, D.B.
626 Milligan, M. Storer, N. Zein, A. Feldstein, R.A. Dweik, Exhaled breath analysis in
627 patients with liver cirrhosis using soft ion flow tube mass spectrometry (SIFT-MS), In
628 C38. Airway inflammation: from mechanisms to non-invasive biomarkers (2011)
629 A4466.

630 [59] R.F. Pfeiffer, Wilson’s disease, *Handb Clin. Neurol.* 100 (2011) pp. 681–709.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

631 [60] T. Hisaki, T. Furumoto, K. Nozaka, K. Kono, T. Odachi, K. Mizumoto, O.
632 Nishimura, S. Koga, Serum zinc and copper changes after gastrectomy in aged patients
633 with gastric cancer, *Jpn. J. Psychol.* 18 (1988) 158–163.

634 [61] G.J. Brewer, F.K. Askari, Wilson's disease: clinical management and therapy, *J.*
635 *Hepatol.* 42 (2005) S13–S21.

636 [62] V. Nangliya, A. Sharma, D. Yadav, S. Sunder, S. Nijhawan, S. Mishra, Study of
637 trace elements in liver cirrhosis patients and their role in prognosis of disease, *Biol.*
638 *Trace Elem. Res.* 165 (2015) 35–40.

639 [63] A. Agarwal, S. Avarebeel, N.S. Choudhary, M. Goudar, C.J. Tejaswini,
640 Correlation of trace elements in patients of chronic liver disease with respect to Child-
641 Turcotte-Pugh scoring system, *J. Clin. Diagn. Res.* 11 (2017) OC25–OC28.

642 [64] A.H. Hunt, R.M. Parr, D.M. Taylor, N.G. Trott, Relation between cirrhosis and
643 trace metal content of liver with special reference to primary biliary cirrhosis and
644 copper, *Br. Med. J.* 2 (1963) 1498–1501.


645 [65] European Association for Study of Liver, EASL clinical practice guidelines:
646 Wilson's disease, *J. Hepatol.* 56 (2012) 671–685.

647 [66] N.C. Nayak, A.R. Chitale, Indian childhood cirrhosis (ICC) & ICC-like diseases:
648 the changing scenario of facts versus notions, *Indian J. Med. Res.* 137 (2013) 1029–
649 1042.

650 [67] R.E. Tanzi, K. Petrukhin, I. Chernov, J.L. Pellequer, W. Wasco, B. Ross, D.M.
651 Romano, E. Parano, L. Pavone, L.M. Brzustowicz, M. Devoto, J. Peppercorn, A.I.
652 Bush, I. Sternlieb, M. Pirastu, J.F. Gusella, O. Evgrafov, G.K. Penchaszadeh, B. Honig,
653 I.S. Edelman, M.B. Soares, I.H. Scheinberg, T.C. Gilliam, The Wilson disease gene is
654 a copper transporting ATPase with homology to the Menkes disease gene, *Nat. Genet.*
655 5 (1993) 344–350.

656 [68] G.J. Brewer, V. Yuzbasiyan-Gurkan, Wilson disease, *Medicine* 71 (1992) 139–
657 164.

658 [69] L.M. Gaetke, C.K. Chow, Copper toxicity, oxidative stress, and antioxidant
659 nutrients, *Toxicology* 189 (2003) 147–163.




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

660 [70] Y. Yoshida, T. Higashi, K. Nouse, H. Nakatsukasa, S.I. Nakamura, A. Watanabe,
661 T. Tsuji, Effects of zinc deficiency/zinc supplementation on ammonia metabolism in
662 patients with decompensated liver cirrhosis, *Acta Med. Okayama* 55 (2001) 349–356.

663 [71] D. Rahelić, M. Kujundžić, Ž. Romić, K. Brkić, M. Petrovečki, Serum
664 concentration of zinc, copper, manganese, and magnesium in patients with liver
665 cirrhosis, *Collegium Antropol.* 30 (2006) 523–528.

666



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

667 **Figure captions**

668 **Fig. 1.** Architecture of the E-nose system used for exhaled breath measurements.

669 **Fig. 2.** Schematic representation of the VE-tongue dedicated to the analysis of urine
670 samples.

671 **Fig. 3.** E-nose responses of: MQ gas sensors when exposed to breath of (a) HC, (b) LCI
672 patient; and interdigitated gas sensors after exposure to VOCs in the breath samples
673 from (c) HC, (d) LCI patient.

674 **Fig. 4.** Responses of the five-electrode arrays of VE-tongue and **insights without Cu**
675 **electrode** towards urine samples from: (a) HC, (b) patient with LCI.

676 **Fig. 5.** Radar plots of E-nose gas sensors responses towards exhaled breath from HC
677 and patient with LCI, expressed by area as a feature.

678 **Fig. 6.** Radar plots of the responses of the VE-tongue electrode array exposed to the
679 two different sets of urine samples, expressed by $P_{t_{ox}}$ as a feature.

680 **Fig. 7.** Unsupervised PCA plot showing data points for: (a) breath samples relating to
681 the two health states with data collected from the E-nose, (b) urine samples relating to
682 the two health states with data collected from the VE-tongue.

683 **Fig. 8.** Supervised DFA plot displaying data points for: (a) breath samples relating to
684 the two health states with data collected from the E-nose, (b) urine samples relating to
685 the two health states with data collected from the VE-tongue.


686 **Fig. 9.** ROC curve displaying data points for: (a) breath samples relating to the two
687 health states with data collected from the E-nose, (b) urine samples relating to the two
688 health states with data collected from the VE-tongue.

689 **Fig. 10.** Unsupervised PCA plot showing data fusion of E-nose and VE-tongue systems.

690 **Fig. 11.** Supervised DFA plot showing data fusion of E-nose and VE-tongue systems.


691 **Fig. 12.** ROC curve showing data fusion of E-nose and VE-tongue systems.

692



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


693 Fig. 1.



694

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


695 Fig. 2.



696

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

697 **Fig. 3.**




698

699

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

700 **Fig. 4.**


Formatted: French (Morocco)



701


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

702 Fig. 5.




703

704




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

705 Fig. 6.



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


706 Fig. 7.



707
708

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


709 **Fig. 8.**




710
711

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

712 Fig. 9.




713




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

714 Fig. 10.




715

716



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

717 **Fig. 11.**




718


719

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

720 **Fig. 12.**



721



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

722 **Table 1**

723 General characteristics of all studied volunteers.

Volunteers					
Groups	Number	Age range (years) Age \pm SD*	Male, number (%)	Smoking habit ⁺	Medication
Liver cirrhosis (LCi)	22	24-79 46 \pm 15	10 (45%)	1 S, 3 Ex.S, 18 NS	- Ciprofloxacin - Aldactone - Autocardyl - Tefovin
Healthy controls (HC)	32	21-64 37 \pm 17	22 (69%)	8 S, 24 NS	—

724 * **SD:** Standard Deviation.

725 + **Smoking habit:** S: Smoker, Ex.S: Ex-Smoker, NS: Non-Smoker.

726

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


727 **Table 2**

728 Commercial gas sensors used in the e-nose system.

Gas Sensors	Target Compounds
MQ-2	Propane, Hydrogen, Methane
MQ-3	Alcohol
MQ-135	Benzene, Ammonia, Carbon dioxide and Nitric oxide
MQ-137	Ammonia
MQ-138	Toluene, Acetone, Methanol, Ethanol and Formaldehyde

729

730




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

731 **Table 3**
732 SVMs results for the classification of 60 breath samples regarding their health states
733 by using the E-nose system with a success rate of 98.33%.

Actual	Predicted	
	LCi patients	HC
LCi patients	29	1
HC	0	30

734




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

735 **Table 4**
736 SVMs results for the classification of 120 urine samples regarding their health states
737 by using the VE-tongue system with a success rate of 97.50%.

Actual	Predicted	
	LCi patients	HC
LCi patients	57	3
HC	0	60

738




1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

739 **Table 5**
740 SVMs results for data fusion of E-nose and VE-tongue systems with a success rate of
741 100%.

Actual	Predicted	
	LCi patients	HC
LCi patients	30	0
HC	0	30

742



1 **Comparative analysis of volatile organic compounds of breath and urine for**
2 **distinguishing patients with liver cirrhosis from healthy controls by using**
3 **electronic nose and voltammetric electronic tongue**

4 Omar Zaim^{a,b}, Alassane Diouf^{a,b}, Nezha El Bari^b, Naoual Lagdali^c, Imane
5 Benelbarhdadi^c, Fatima Zohra Ajana^c, Eduard Llobet^d and Benachir Bouchikhi^{a,*}

6 ^aSensor Electronic & Instrumentation Group, Department of Physics, Faculty of
7 Sciences, Moulay Ismaïl University of Meknes, B.P. 11201, Zitoune, Meknes,
8 Morocco.

9 ^bBiosensors and Nanotechnology Group, Department of Biology, Faculty of Sciences,
10 Moulay Ismaïl University of Meknes, B.P. 11201, Zitoune, 50003 Meknes, Morocco.

11 ^cMohammed V University, Ibn Sina Hospital, Department of Medical Gastroenterology
12 C, Rabat, Morocco.

13 ^dDepartment of Electronic Engineering, Universitat Rovira i Virgili, MINOS-EMaS,
14 Microsystems and Nanotechnologies for Chemical Analysis, Avinguda Països
15 Catalans, 26, 43007 Tarragona, Spain.

16
17
18
19
20
21
22
23
24
25 ^{*} Corresponding author:

26 Postal address: B.P. 11201, Zitoune, Meknes, Morocco

27 Tel: +212 535 53 88 70; Fax: +212 535 53 68 08

28 Email: benachir.bouchikhi@gmail.com

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

29 **ABSTRACT**

30 Advanced stage detection of liver cirrhosis (LCi) would lead to high mortality rates in
31 patients. Therefore, accurate and non-invasive tools for its early detection are highly
32 needed using human emanations that may reflect this disease. Human breath, along with
33 urine and blood, has long been one of the three main biological media for assessing
34 human health and environmental exposure. The primary objective of this study was to
35 explore the potential of using volatile organic compounds (VOCs) assay of exhaled
36 breath and urine samples for the diagnosis of patients with LCi and healthy controls
37 (HC). For this purpose, we used a hybrid electronic nose (E-nose) combining two sensor
38 families, consisting of an array of five commercial chemical gas sensors and six
39 interdigitated chemical gas sensors based on pristine or metal-doped WO₃ nanowires
40 for sensing volatile gases in exhaled breath. A voltammetric electronic tongue (VE-
41 tongue), composed of five working electrodes, was dedicated to the analysis of urinary
42 VOCs using cyclic voltammetry as a measurement technique. 54 patients were recruited
43 for this study, comprising 22 patients with LCi, and 32 HC. The two-sensing systems
44 coupled with pattern recognition methods, namely Principal Component Analysis
45 (PCA) and Discriminant Function Analysis (DFA), were trained to classify data clusters
46 associated with the health status of the two groups. The diagnostic performances of the
47 E-nose and VE-tongue systems were studied by using the receiver operating
48 characteristic (ROC) method. The use of the E-nose or the VE-tongue separately,
49 trained with these appropriate classifiers, showed a slight overlap indicating no clear
50 discrimination between LCi patients and HC. To improve the performance of both
51 electronic sensing devices, an emerging strategy, namely a multi-sensor data fusion
52 technique, was proposed as a second aim to overcome this shortcoming. The data fusion
53 approach of the two systems, at a medium level of abstraction, has demonstrated the
54 ability to assess human health and disease status using non-invasive screening tools
55 based on exhaled breath and urinary VOC analysis. This suggests that exhaled breath
56 as well as urinary VOCs are specific to a disease state and could potentially be used as
57 diagnostic methods.

58 **Keywords:** Liver cirrhosis; volatile organic compounds; exhaled breath analysis; urine
59 analysis; electronic sensing system; data fusion.

60 **1. Introduction**

61 Liver disease has become a major global health problem. Indeed, it is responsible
62 for the death of two million people per year worldwide. Of these, one million are due
63 to complications of cirrhosis [1,2]. This mortality is due to symptoms that are usually
64 detected at a very advanced stage and in a metastatic state [3]. Although many efforts
65 have been made in recent years, liver cirrhosis (LCi) still causes many deaths
66 worldwide. This mortality is also due to the relatively high cost of treatment in some
67 parts of the world [4-6]. Generally, patients use drugs and surgery to hope to prolong
68 their lives.

69 To counteract the progression of the disease, early detection or intervention would
70 be of great interest. This would avoid or delay clinical interventions. For this purpose,
71 the development of effective predictive methods would be of paramount importance.

72 Efforts to develop therapeutic methods are still not effective enough. There is
73 therefore a need to improve early detection methods. Early detection and accurate
74 diagnosis of the onset of the disease are the most promising approaches to accelerate
75 the healing process or significantly reduce the associated mortality.

76 Exhaled breath contains volatile organic compounds (VOCs) that may reflect
77 disease. The development of non-invasive methods to monitor the progression of
78 diseases would offer more advantages than other conventional methods [7]. Several
79 studies have even identified VOCs emitted from the breath of the affected person as
80 indicators or markers of disease [8,9]. In other words, the onset of various diseases or
81 metabolic changes is accompanied by a significant change in the concentration of
82 certain VOCs in exhaled breath [10].

83 Besides, it is known that the human body reacts to infections and the development
84 of diseases in various ways by producing biomarkers in biological fluids, which then
85 act as a mirror of the diseases. For example, the composition of urine varies according
86 to the health status of the person [11,12]. Thus, the chemical compounds in urine are
87 good indicators because they reveal the general state of the patient's body and thus make
88 it possible to diagnose certain dysfunctions or pathologies. Depending on the
89 pathology, specific VOCs emanate from the human body. They provide information on
90 the state of health of the individual. VOCs analysis would therefore be a new approach
91 to diseases monitoring. Some studies have even established a link between urinary VOC

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

92 profiles and infectious diseases [13]. These compounds in urine, whether electro-active
93 or not, have different electrochemical activities.

94 The aim is to detect the disease at an early stage so that treatment can be started
95 quickly, which could reduce the severity and mortality of the disease. Therefore, it is
96 advisable to combine the analysis of exhaled breath samples with non-invasive body
97 fluids analysis [14-16].

98 The main disadvantage of traditional diagnostic tests is the long delay before the test
99 can be performed. Furthermore, despite their efficiency, sensitivity and often
100 specificity, chromatography techniques have many drawbacks and can only be used in
101 structured laboratories. In addition, some techniques may require patient irradiation or
102 surgery and test results are not obtained immediately. A lack of reliable tests and the
103 opacity of many clinical tests of liver function (from imaging, blood sampling to liver
104 biopsy) are also noticed. Then, these negative aspects of traditional methods have paved
105 the way for the wider development of multi-sensory systems (E-Nose and VE-tongue)
106 as useful alternatives to conventional methodologies. They are simple, reliable, cost-
107 effective, fast and can be used in complex environments. In addition, they can be used
108 on site, even by unskilled personnel [17-19].

109 For this purpose, multi-sensor-based detection systems, such as electronic noses
110 and tongues, have become serious candidates in recent years. These devices are based
111 on cross-selective sensor arrays. These systems have certain advantages due to their
112 known specific characteristics [20,21]. These detection approaches are based on
113 sensor arrays that can analyse samples with different chemical signatures [22,23]. The
114 samples are classified by distinguishing these chemical signatures using chemometric
115 methods. Electronic noses and tongues can be used in many fields such as the
116 automotive industry [24], medicine and pharmaceuticals [25], military industry [26],
117 wastewater treatment [27], and agriculture [28]. The biomedical field, such as analysis
118 of human breath and urine, is the focus of this report. Recently, a number of works
119 using multi-sensor systems, so-called E-nose and tongue are devoted to LCi [29,30].

120 However, the individual use of an electronic nose or tongue only reflects one aspect
121 of the sample (smell or taste). In order to obtain more in-depth information while
122 minimising the limitation of the detection systems, the data fusion technique can be
123 used to generate a global signature associated with the sensitivity of both devices.
124 According to some literature [31-33], data fusion technique is categorised as "low
125 level", "medium level" and "high level", depending on the processing stage at which

126 fusion takes place. Therefore, the data fusion strategy is an effective tool for using
127 compatible measurement data from devices.

128 When using an electronic nose and tongue, several studies have exploited data
129 fusion. They include the prediction of the mixing ratio of old frying oil [34,35], the
130 classification of different samples of honey and rice [36,37], the non-destructive
131 detection of fish freshness [38], and the evaluation of tea and strawberry juice flavours
132 [39].

133 Taking all these considerations into account, the aim of this study was to use an E-
134 nose in conjunction with a VE-tongue combined with pattern recognition methods to
135 analyse exhaled breath and human urine samples from LCi patients and HC. Indeed,
136 the key clue was to merge the data from both measurement systems to improve their
137 discrimination performance when taken separately.

138 2. Materials and methods

139 2.1. Exhaled breath and urinary collection

140 A total of 54 volunteers has participated in this study including 22 patients with LCi,
141 and 32 HC. The patient samples, used in this study, are in the primary stage of disease.
142 **Table 1** illustrates the general characteristics of all studied volunteers. In this study,
143 only adult volunteers were considered. Persons who had consumed medication, drugs,
144 alcohol, tobacco, drink or food before 12 noon were automatically excluded from the
145 study.

146 In the literature there is no standard method for breath sampling [40] and there are
147 different protocols for sample analysis [41]. Tedlar® bags have been shown to have
148 acceptable sample storage properties compared to other bags made of different
149 materials [42].

150 The volunteers were asked to rinse their mouth before collecting exhaled breath
151 samples in Tedlar® bags with mouthpiece. Three breath samples were collected per
152 each volunteer. Indeed, the volunteer blows into commercial 2 L Tedlar® bags
153 (Supelco Inc., Belfonte, PA. USA) through a one-way valve. This valve prevents
154 outside air from mixing with the collected breath. Before and after each breath sample,
155 the Tedlar® bags are cleaned 3 times with synthetic air.

156 Besides, morning urine samples are collected in 25 mL vials.

157 An approval was issued by the Biomedical Research Ethics Committee of the
158 Avicenne University Hospital (Mohammed V University, Rabat, Morocco). Prior to the
159 collection of the samples, all the volunteers signed a consent agreement.

160 2.2. Electronic sensing systems

161 Electronic nose and tongue have been used to analyze volatile organic compounds
162 (VOCs) in exhaled breath and urine samples collected from patients with LC and HC,
163 respectively.

164 2.2.1. E-nose experimental set-up

165 **Fig. 1** shows a schematic diagram of the system developed for the analyse of exhaled
166 breath gas, which consists of a Tedlar[®] bag containing the samples, a micro-pump (flow
167 rate of 200 L/min) to transport the analyte to a sensor chamber, a USB-6212 NI module
168 for data acquisition and a man-machine interface for monitoring and recording the
169 sensor responses. The E-nose comprises:

- 170 • Five chemical sensors (MQ-2, MQ-3, MQ-135, MQ-137 and MQ-138)
171 purchased from Henan Hanwei Electronics Co, (Zhengzhou, China). The
172 commercial sensors and their target compounds are listed in **Table 2**.
- 173 • Six interdigitated gas sensors (Pristine WO₃, Pt/WO₃, Au/Pt/WO₃, Au/WO₃,
174 Ni/WO₃ and Fe/WO₃). These nanostructures were deposited on alumina
175 substrates. Tungsten hexacarbonyl (WC₆O₆) was used as a precursor for
176 preparing tungsten trioxide (WO₃) nanostructures, which were synthesized
177 according to the process described in our previous work [43]. For the analysis
178 of breath samples, these interdigital chemical gas sensors are used at their
179 optimal operating temperatures as determined in a reported study of our
180 laboratory [44]. During the measurement, the sensors were irradiated with
181 UV light at 394 nm. The optimum temperature for good sensitivity was
182 100°C (for pristine WO₃, Pt/WO₃, Pt/Au/WO₃), and 160°C (for Au/WO₃,
183 Ni/WO₃, Fe/WO₃).
- 184 • A relative humidity sensor (Honeywell HIH 4000-002), and a temperature
185 sensor (LM35DZ) from National Semiconductor.

186 For each volunteer, three replica breath samples were collected. They were then
187 transferred to the sensor chamber by pumping the analyte for 10 minutes. The responses
188 of the gas sensors are recorded as conductance vs. time.

2.2.2. VE-tongue experimental set-up

The scheme of the experimental VE-tongue used for urine samples analysis is shown in [Fig. 2](#). It is a conventional electrochemical cell based on a three-electrode configuration. Briefly, it consists of an Ag/AgCl reference electrode and an array of five working electrodes: copper (Cu), glassy carbon (GC), platinum (Pt), palladium (Pd), gold (Au), and an auxiliary electrode made of platinum.

After explaining the measurement protocol to the volunteer, a new polystyrene bottle was given to him to get his urine sample. The VE-tongue analysis of the urine is immediately performed after the urine is received without any pre-treatment. Once the measurement is done, the urine sample is stored at -4°C .

Electrochemical measurements are carried out by immersing the electrodes in a vessel containing the sample. The measurements are then initiated, and a data acquisition device (PalmSens³ potentiostat, Netherlands) was used to automatically store the output data of the electrode responses. The CV technique was configured as follows: the potential scanning window was between -0.2 to 0.6 V. The scanning was performed at 50 mV/s. To avoid possible measurement errors due to contamination of the electrode surfaces, the electrodes were all rinsed with piranha and polished before and after each measurement. This also helps to minimize drift.

During electrochemical measurements, the electrode responses are recorded as voltammograms. For the sake of repeatability in the measurements, 6 measurement repetitions were carried out for each urine sample. The total response obtained from the analyzed analyte was therefore 6 voltammograms \times 5 electrodes per urine sample.

These experiments were carried out at room temperature (25°C). After analysis of the exhaled breath and urine samples, a very large database was obtained, which made interpretation difficult. To overcome this drawback, relevant features were extracted from the responses of both systems (E-nose and VE-tongue) to facilitate visualization, interpretation and understanding.

2.3. Data pre-processing

Sensor response drift is a general issue that is considered in this work. Numerous correction techniques have been tested on pre-treatment data to reduce it [\[45\]](#).

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

219 Indeed, to reduce the effect of sensor drifts, normalization procedure of each gas
220 sensor response ($\frac{G-G_0}{G_0}$) is used where G is the measured conductance and G₀ is the
221 baseline [45].

222 To simplify the processing of multivariate data, only the variables of interest are
223 retained in the initial data. These variables retain as much information as possible from
224 these responses. In this study, the analysis of the responses of E-nose system was
225 carried out using the two variables cited below:

- 226 • **ΔG** = ($G_S - G_0$): The difference between the stabilised conductance (G_S)
227 and the initial conductance (G_0);
- 228 • **AUC**: Area under the response curve of the sensor measured by a trapezoidal
229 method. The area considered is between 1 and 9 minutes of the measurement
230 time.

231 Furthermore, for processing the VE-tongue database, two eigenvalues related to the
232 output current values were exacted from the cyclic voltammogram response of each
233 working electrode, including:

- 234 • **Pt_{ox}** : Maximum signal slope in the first half wave (oxidation)
- 235 • **Area**: Area under the response curve of the sensor.

236 In this study, for the E-nose, 162 breath samples (54 volunteers * 3 Tedlar bags)
237 were measured and 2 features (ΔG and AUC) were used. These 2 features were
238 extracted from the response of each gas sensor. Since we have 11 gas sensors, for each
239 breath sample, 22 features were extracted. Therefore, for all samples, we had a total of
240 3564 variables (i.e. 162 samples * 22). The same logic was used for the VE-tongue.
241 Thus, 7128 variables were extracted (i.e. 324 samples*22).

242 2.4. Data analysis

243 After extraction of the variables, data processing algorithms (PCA, DFA) are used
244 to classify the analyzed samples for better visualisation and interpretation [46].
245 Chemometric techniques are crucial tools for obtaining a practical system capable of
246 characterising a wide diversity of compounds [47].

247 The aim of using these methods in this work is to evaluate the effectiveness of the
248 E-nose and VE-tongue in discriminating between the two groups based on breath and
249 urine samples using both supervised and unsupervised methods.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

250 PCA is an unsupervised linear method that uses an orthogonal transformation to
251 reduce the dimensionality of multivariate data [48,49]. This transformation is applied
252 so that the principal components (PCs) have the greatest possible variance while
253 remaining orthogonal. In this study, PCA was used to process multivariate data from
254 the E-nose and VE-tongue to obtain a clear illustration in a low-space projection.

255 DFA is a supervised chemometric method whose effectiveness has been proven in
256 many applications of electronic sensing systems [50]. With the DFA method, the
257 discriminating functions are determined in such a way that the ratio within a group is
258 minimised (intra-class variance). At the same time, it maximises the ratio between
259 groups (inter-class variance).

260 A ROC curve is a graph that illustrates the diagnostic ability of a binary classification
261 system as a function of the variation in its discrimination threshold. The ROC curve is
262 obtained by plotting the true positive rate (TPR) against the false positive rate (FPR)
263 for different thresholds. The true positive rate is called sensitivity, recall or probability
264 of detection [51] in machine learning. The false positive rate is known as the false alarm
265 probability [51] and can be calculated as follows (1 - specificity).

266 SVM is a supervised nonlinear chemometric technique based on the notion of
267 maximum margin. The maximum margin is the distance between the separation
268 boundary and the nearest samples [52]. SVMs allows to draw a hyperplane for this
269 separation. There is a multitude of valid hyperplanes. However, SVMs searches among
270 the valid hyperplanes for the one that not only passes "in the middle" of the points of
271 the two classes but also maximizes the margin.

272 2.5. Multisensory data fusion approach

273 In this study, a data fusion strategy was adopted. The main objective of using this
274 approach was to improve the classification performance obtained using the two
275 electronic devices individually. Here, medium level data fusion was applied to
276 compensate for the limitations in terms of classification/discrimination of HC and LCi
277 patient samples by the used electronic sensing systems. In this approach, the fusion is
278 done using the features extracted from the E-nose and VE-tongue data [39,53]. It is
279 obvious that the number of features from the two systems should be similar when
280 merging data using the medium level abstraction approach. If the number of features
281 from one instrument is significantly higher, they could dominate the merged dataset. In

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

282 our case, the E-nose dataset is larger than that of the VE-tongue. For this reason, since
283 only 5 electrodes were used for the VE-tongue, an appropriate method of selecting the
284 five most discriminating gas sensors was carried out in order to obtain a similar
285 dimensionality of both matrices. Therefore, using the medium level abstraction
286 approach, the datasets obtained from each multi-sensor system (E-nose and VE-tongue)
287 were merged into a single matrix of 162 samples on 4 features (ΔG and area for the E-
288 nose; Ptox and area for the VE-tongue).

289 3. Results and discussion

290 3.1. Analysis of VOCs in exhaled breath by E-nose system

291 Sensor responses were recorded during the 10 minutes of breath exposure, followed
292 by 10 minutes of return to baseline under synthetic air. **Fig. 3** displays the responses of
293 the two families of gas sensor arrays towards exhaled breath samples of HC and LCi.
294 As shown in **Fig. 3**, the response of the sensor array to the exhaled breath gas was
295 directly related to the gas detection and pattern identification. The MQ-138 sensor of
296 **Fig. 3(b)** showed higher sensitivities than the other sensors. Many studies have been
297 performed on the analyze of breath VOC biomarkers from LCi patients and reported
298 that volatile biomarkers in breath associated with liver cirrhosis are Methanol [54-56],
299 Dimethyl sulfide [57,58], Ethanol and Toluene [58]. Though the other sensors showed
300 relatively low signals, there were differences between LCi patients and HC (**Fig 3(a)**).
301 We can notice that the gas reaction was completed after 600 s, whereas the desorption
302 of the gas was completed after around 30 s for MQ sensors. However, this time to return
303 to the baseline remains longer for interdigitated chemical gas sensors based on pristine
304 or metal-doped WO_3 nanowires (**Fig. 3 (c,d)**). Besides, Au/ WO_3 sensor response (**Fig**
305 **3(d)**) provided higher response toward LCi patient's breath sample than to the HC (**Fig**
306 **3(c)**). This behaviour can be justified by the difference in VOC concentrations in the
307 breath related to HC and LCi patients [6,23].

308 3.2. Analysis of urinary VOCs by VE-tongue

309 **Fig. 4** shows different electrochemical responses, depending on the health state
310 associated with the urine samples that were analysed. These irreversible responses are
311 different in terms of shape and amplitude. However, oxidation processes are only
312 observed when using Cu working electrode. This oxidation effect is more pronounced
313 in urine samples of patients with LCi. This is probably due to abnormal variation of

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
314 copper level in the body of LCi patients and released in urine [59-68]. It should be noted
315 that the intensity of the voltammograms yield by Cu working electrode corresponding
316 to urine samples of patients with LCi (**Fig. 4(b)**) is higher than those of HC (**Fig. 4(a)**).
317 The oxidation peak is around 0.30 V for LCi (**Fig. 4(b)**), while the Cu electrode admits
318 a small oxidation peak at around 0.02 V for the urine sample of HC (**Fig. 4(a)**). With
319 the Cu electrode, the voltammograms demonstrate metal oxidation, forming copper
320 ions in urine samples, but with different trend for LCi. According to the literature,
321 copper primarily deposits in the liver and the lethal dose is about 10-20 g [69]. On one
322 hand, *A. Amit et al.* and *Y. Yoshida et al.* report that liver problems modify the
323 metabolism of trace elements. In this case, they declare the presence of either a high
324 presence of copper or a deficiency of zinc (Zn) [63,70]. In this purpose, *D. Rahelic et*
325 *al.* explains the role of copper in the redox process [71]. Consequently, the proposed
326 VE-tongue provides findings that show that the state of health influences the chemical
327 composition of the urine and corroborates the literature.

25 26 27 28 29 30 31 32 33 34 35 36 37 38 39 40 41 42 328 3.3. Radar plot results

329 The sensors are not specific to one compound. However, each sensor is sensitive to
330 several compounds. The combination of the responses allows plotting a specific
331 chemical signature. After the features' extraction step, the radar plot was used to see if
332 there were any differences or similarities in terms of the chemical signatures of the
333 various breath and urine samples from patients with LCi and HC. **Fig. 5** shows the radar
334 plot results highlighting the contribution of the E-nose gas sensors. These plots were
335 constructed using the area value as a feature. There is a clear variation in pattern
336 between the breath-prints of the two groups.

337 **Fig. 6** shows the radar plots of the two sets of urine samples obtained after
338 extraction of the relevant features from the voltammograms. Each representation has a
339 particular chemical signature in their taste profile, although there are some similarities.
340 The majority of the electrodes showed similar behaviour for the two groups except for
341 Pd electrode. This could strongly influence the classification performance of the VE-
342 tongue, thus generating an overlap in the sample patterns.

54 55 56 57 58 59 60 61 62 63 64 65 343 3.4. PCA discrimination results

344 The discrimination results of the two sensing systems individually by using PCA are
345 depicted in **Fig. 7**. Using two features (ΔG and AUC), the PCA results for the E-nose
346 (**Fig. 7(a)**) indicate a data variance of 61.98%, which was explained by the first three

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

347 principal components (PCs). This three-dimensional PCA plot shows a classification
348 among the breath patterns of LCI patients and HC with slight overlapping between the
349 two clusters.

350 Besides, the VE-tongue discrimination results obtained by applying PCA are shown
351 in **Fig. 7(b)**, where all three PCs contributed to a score of 81.38%. Here, the samples of
352 the LCI patients also overlapped with those of the HC. This is probably due to the
353 similarity of the electrochemical responses of the majority of the electrodes.

354 3.5. DFA discrimination results

355 The same dataset was used to perform a treatment using a supervised method, called
356 DFA. It was used to distinguish between different samples of breath and urine
357 according to their health states. The results of the DFA after its application to the
358 responses of the two systems are shown in **Fig. 8**. The same features as for the PCA
359 were used. The results in **Fig. 8(a)** show a discrimination between LCI patients and HC
360 breath samples. In contrast, the discriminatory feasibility of the VE-tongue, shown in
361 **Fig. 8(b)**, does not lead to a perfect separation between LCI and HC samples. These
362 results confirm those obtained by the PCA analysis and suggest the use of data fusion
363 to recognise the two health states.

364 3.6. Receiver operating characteristic (ROC) results

365 ROC curves for the E-nose and VE-tongue data were plotted. AUC values were
366 calculated to assess the diagnostic value of each data item. The ROC curve and AUC
367 analysis of the logistic regression were performed to explore the diagnostic
368 performances of the E-nose and VE-tongue models. **Fig. 9(a)** shows the ROC curve of
369 the E-nose data with an AUC of 0.965 corresponding to the analysis of LCI and HC
370 breath samples.

371 Besides, **Fig. 9(b)** shows the ROC curve of the VE-tongue model data with an AUC
372 of 0.950 for the distinction of urine samples corresponding to LCI and HC. These results
373 show that the diagnostic performances of two multi-sensor systems is significantly
374 significant. Furthermore, the diagnostic performance of the E-nose model is higher than
375 that of the VE-tongue model.

376 3.7. SVMs classification results

377 The dataset trained for 20 volunteers (10 LCi and 10 HC patients) of balanced age
378 was used to run the SVMs method. It was used to distinguish between different breath
379 and urine samples according to their health status.

380 **Table 3** shows the SVMs results of the classification of 60 breath samples (20
381 volunteers providing 3 samples each). The rows of the table indicate the actual health
382 states and the columns the predicted states. The SVMs method achieved a success rate
383 of 98.33% in the recognition of the two groups studied (LCi and HC). As can be seen
384 from the table, one error was detected: a sample belonging to LCi was classified in the
385 HC group.

386 Besides, **Table 4** presents the SVMs results when analyzing the data from the VE-
387 tongue for 120 urine samples. The same trend as for the E-nose is observed with the
388 occurrence of three errors and a success rate of 97.50%.

389 3.8. Data fusion results

390 3.8.1. PCA classification results

391 Using data fusion, the PCA method was applied to discriminate the two types of
392 samples. **Fig. 10** shows the discrimination results obtained by combining the data from
393 the two systems, where all three principal components contributed with a score of
394 64.23%. Indeed, we can notice both groups are well discriminated, demonstrating the
395 ability of the combination of two systems to overcome the overlap observed previously.
396 The close linkage of biological emanations to health status provides a unique signature.
397 This explains the good discrimination obtained by merging the data as opposed to
398 separating them.

399 3.8.2. DFA classification results

400 DFA was also used to examine the ability of the data fusion technique to improve
401 the classification of different samples according to their health status. **Fig. 11** shows
402 the first two DFA functions for the classification of HC and LCi patients using data
403 fusion of the E-nose and VE-tongue systems. The result reveals a perfect discrimination
404 between HC and LCi patients. Therefore, the processing of the data by the DFA
405 technique reveals the effectiveness of the proposed data fusion method in distinguishing
406 HC and LCi patients.

3.8.3. Receiver operating characteristic (ROC) results

A ROC analysis was also performed to evaluate the diagnostic performance after data fusion to improve the classification of different samples according to their health status. **Fig. 12** shows the ROC curve corresponding to the merged data of the two devices with a very good AUC of 0.999. This result shows that the diagnostic performance of the model obtained after data fusion is superior to those found using the E-nose and VE-tongue data individually. These results confirm the effectiveness of merging data from two compatible systems to successfully distinguish HC and LCi patients.

3.8.4. SVMs classification results

In order to enhance the SVMs classifications obtained by taking the two measurement systems individually, SVMs was applied to the merged data. For this purpose, 20 age-balanced volunteers (10 LCi and 10 HC patients) were considered.

Table 5 shows the results of the SVMs classification for the fusion of the E-nose and VE-tongue data. A very good result by the SVMs method is achieved with a success rate of 100% for the recognition of LCi and HC volunteers. In the light of this result, it can be concluded that the data fusion technique is a good way to improve the classification of different samples.

4. Conclusion

In this work, an electronic nose and tongue were used to analyse breath and urine samples from patients with LCi and HC. With the help of pattern recognition methods, the two electronic devices, taken individually, showed limitations in terms of discrimination of the two study groups. To overcome the limitation of the individual systems, the data fusion of the E-nose and VE-tongue provided very satisfactory results in terms of discrimination and classification. Indeed, the PCA results obtained from the merged data showed a good classification of the different breath and urine samples according to their health status. In addition, the supervised method (DFA) was able to clearly differentiate between LCi patients and HC. Moreover, the diagnostic result of data fusion obtained by ROC curve is superior to those found using the E-nose and VE-tongue data individually. The advantage of this study is the proposal of electronic sensing systems as alternative tools to conventional techniques, which have many drawbacks for the analysis of this disease. This demonstrates that the two proposed

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

439 devices have a classification and predictive capability that would certainly contribute
440 to facilitating the early diagnosis of diseases. In view of the results of this study, and
441 thanks to their portability and speed, they could therefore be used as non-invasive
442 diagnosis for other diseases.

443 **Declaration of Competing Interest**

444 The authors declare that they have no known competing financial interests or
445 personal relationships that could have appeared to influence the work reported in this
446 paper.

447 **Acknowledgement**

448 Authors gratefully acknowledge Moulay Ismaïl University of Meknes for financial
449 support of the project “Research support”. The authors thank and wish to express their
450 gratitude to Dr. Tarik SAIDI for the excellent technical assistance in the fabrication
451 process of WO₃ sensors.

452 **References**

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 453 [1] S.K. Asrani, H. Devarbhavi, J. Eaton, P.S. Kamath, Burden of liver diseases in the
454 world, *J. Hepatol.* 70 (2019) 151–171.
- 455 [2] A.A. Mokdad, A.D. Lopez, S. Shahraz, R. Lozano, A.H. Mokdad, J. Stanaway, M.
456 Naghavi, Liver cirrhosis mortality in 187 countries between 1980 and 2010: a
457 systematic analysis, *BMC Med.* 12 (2014) 145.
- 458 [3] N. Afdhal, J. McHutchison, R. Brown, I. Jacobson, M. Manns, F. Poordad, B.
459 Weksler, R. Esteban, Thrombocytopenia associated with chronic liver disease, *J.*
460 *Hepatol.* 48 (2008) 1000–1007.
- 461 [4] M. Mohammadi, N. Zarghami, M. Hedayati, S. Ghaemmaghami, R.M. Yamchi, M.
462 Mohaddes, Visfatin effects on telomerase gene expression in AGS gastric cancer cell
463 line, *Indian J. Cancer* 52 (2015) 32–35.
- 464 [5] S. Kumar, J. Huang, N. Abbassi-Ghadi, H.A. Mackenzie, K.A. Veselkov, J.M.
465 Hoare, G.B. Hanna, Mass spectrometric analysis of exhaled breath for the identification
466 of volatile organic compound biomarkers in esophageal and gastric adenocarcinoma,
467 *Ann. Surg.* 262 (2015) 981–990.
- 468 [6] K.E. Pijls, A. Smolinska, D.M. Jonkers, J.W. Dallinga, A.A. Masclee, G.H. Koek,
469 F.J. Van Schooten, A profile of volatile organic compounds in exhaled air as a potential
470 non-invasive biomarker for liver cirrhosis, *Sci. Rep.* 6 (2016) 1–8.
- 471 [7] C. Ghosh, V. Singh, J. Grandy, J. Pawliszyn, Recent advances in breath analysis to
472 track human health by new enrichment technologies, *J. Sep. Sci.* 43 (2020) 226–240.
- 473 [8] C.M. Durán-Acevedo, J.M. Cáceres-Tarazona, Low-cost desorption unit coupled
474 with a gold nanoparticles gas sensor arrays for the analysis of volatile organic
475 compounds emitted from the exhaled breath (gastric cancer and control samples),
476 *Microelectron. Eng.* 237 (2020) 111483.
- 477 [9] M. Rondanelli, F. Perdoni, V. Infantino, M.A. Faliva, G. Peroni, G. Iannello, M.
478 Nichetti, T.A. Alalwan, S. Perna, C. Cocuzza, Volatile organic compounds as
479 biomarkers of gastrointestinal diseases and nutritional status, *J. Anal. Methods Chem.*
480 2019 (2019) 1–15.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 481 [10] G. Lubes, M. Goodarzi, GC–MS based metabolomics used for the identification
482 of cancer volatile organic compounds as biomarkers, *J. Pharm. Biomed. Anal.* 147
483 (2018) 313–322.
- 484 [11] M. Shao, H. Lu, M. Yang, Y. Liu, P. Yin, G. Li, Y. Wang, L. Chen, Q. Chen, C.
485 Zhao, Q. Lu, T. Wu, G. Ji, Serum and urine metabolomics reveal potential biomarkers
486 of T2DM patients with nephropathy, *Ann. Transl. Med.* 8(5) (2020) 1–22.
- 487 [12] P.M. Villeneuve, S.M. Bagshaw, Assessment of urine biochemistry, In *Critical*
488 *Care Nephrology*, (2019) pp. 323–328.
- 489 [13] Q. Gao, W.Y. Lee, Urinary metabolites for urological cancer detection: a review
490 on the application of volatile organic compounds for cancers, *Am. J. Clin. Exp. Urol.* 7
491 (2019) 232.
- 492 [14] A. Krilaviciute, C. Stock, M. Leja, H. Brenner, Potential of non-invasive breath
493 tests for preselecting individuals for invasive gastric cancer screening endoscopy, *J.*
494 *Breath Res.* 12 (2018) 036009.
- 495 [15] S.R. Markar, J. Lagergren, G.B. Hanna, Research protocol for a diagnostic study
496 of non-invasive exhaled breath analysis for the prediction of oesophago-gastric cancer,
497 *BMJ open* 6 (2016) e009139.
- 498 [16] L. Xu, Y.H. Qu, X.D. Chu, R. Wang, H.H. Nelson, Y.T. Gao, J.M. Yuan, Urinary
499 levels of N-nitroso compounds in relation to risk of gastric cancer: findings from the
500 shanghai cohort study, *PloS one* 10 (2015) e0117326.
- 501 [17] E. Turppa, I. Polaka, E. Vasiljevs, J.M. Kortelainen, G. Shani, M. Leja, H. Haick,
502 Repeatability study on a classifier for gastric cancer detection from breath sensor data,
503 In 19th IEEE International conference on bioinformatics and bioengineering (2019)
504 450–453.
- 505 [18] D. Hashoul, H. Haick, Sensors for detecting pulmonary diseases from exhaled
506 breath, *Eur. Respir. J.* 28 (2019) 190011.
- 507 [19] K. Matsumoto, Y. Murakami, Y. Shimizu, H. Takahiro, I. Wataru, I. Masatsugu,
508 Electronic nose to distinguish bladder cancer by urinary odour feature: A pilot study,
509 *Cancer Biomark.* 28 (2020) 33–39.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 510 [20] W. Hu, L. Wan, Y. Jian, C. Ren, K. Jin, X. Su, X. Bai, H. Haick, M. Yao, W. Wu,
511 Electronic noses: from advanced materials to sensors aided with data processing, *Adv.*
512 *Mater. Technol.* 4 (2019) 1800488.
- 513 [21] A. Diouf, M. Moufid, D. Bouyahya, L. Österlund, N. El Bari, B. Bouchikhi, An
514 electrochemical sensor based on chitosan capped with gold nanoparticles combined
515 with a voltammetric electronic tongue for quantitative aspirin detection in human
516 physiological fluids and tablets, *Mater. Sci. Eng. C* 110 (2020) 110665.
- 517 [22] A. De Vincentis, G. Pennazza, M. Santonico, U.V. Gentilucci, G. Galati, P. Gallo,
518 C. Vernile, C. Pedone, R.A. Incalzi, A. Picardi, Breath-print analysis by e-nose for
519 classifying and monitoring chronic liver disease: a proof-of-concept study, *Sci. Rep.* 6
520 (2016) 25337.
- 521 [23] K. Eng, N. Alkhouri, F. Cikach, N. Patel, C. Yan, D. Grove, R. Lopez, E. Rome,
522 R.A. Dweik, Analysis of breath volatile organic compounds in children with chronic
523 liver disease compared to healthy controls, *J. Breath Res.* 9 (2015) 026002.
- 524 [24] M. Morvan, T. Talou, A. Gaset, J.F. Beziau, Electronic-nose systems for control
525 quality applications in automotive industry, *Sens. Actuators B Chem.* 69(3) (2000) 384-
526 388.
- 527 [25] L. Zhu, R.A. Seburg, E. Tsai, S. Puech, J.C. Mifsud, Flavor analysis in a
528 pharmaceutical oral solution formulation using an electronic-nose, *J. Pharm. Biomed.*
529 *Anal.* 34(3) (2004) 453-461.
- 530 [26] M. Winkler, K.D. Tuchs, K. Hughes, G. Barclay, Theoretical and practical aspects
531 of military wireless sensor networks, *J. Telecommun. Inf. Technol.* (2008) 37-45.
- 532 [27] M.C. Martínez-Bisbal, E. Loeff, E. Olivas, N. Carbó, F.J. García-Castillo, J.
533 López-Carrero, I. Tormos, F.J. Tejadillos, J.G. Berlanga, R. Martínez-Máñez, M.
534 Alcañiz, J. Soto, A voltammetric electronic tongue for the quantitative analysis of
535 quality parameters in wastewater, *Electroanalysis* 29(4) (2017) 1147-1153.
- 536 [28] I.M. Apetrei, C. Apetrei, Detection of virgin olive oil adulteration using a
537 voltammetric e-tongue, *Comput. Electron. Agric.* 108 (2014) 148-154.
- 538 [29] A. De Vincentis, G. Pennazza, M. Santonico, U. Vespasiani-Gentilucci, G. Galati,
539 P. Gallo, A. Zompanti, C. Pedone, R.A. Incalzi, A. Picardi, Breath-print analysis by e-

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

540 nose may refine risk stratification for adverse outcomes in cirrhotic patients, *Liver Inter.*
541 37(2) (2017) 242-250.

542 [30] M. Muley, U. Vespasiani-Gentilucci, A. De Vincentis, M. Santonico, G. Pennazza,
543 S. Sanguedolce, C. De Luca, F. Plotti, A. Picardi, R. Antonelli-Incalzi, Voltammetric
544 analysis for distinguishing portal hypertension-related from malignancy-related ascites:
545 A proof of concept study, *Plos one* 15(5) (2020) e0233350.

546 [31] A. Rudnitskaya, D. Kirsanov, A. Legin, K. Beullens, J. Lammertyn, B.M. Nicolai,
547 J. Irudayaraj, Analysis of apples varieties—Comparison of electronic tongue with
548 different analytical techniques, *Sensor Actuat. B-Chem.* 116 (2006) 23–28.

549 [32] C. Di Natale, R. Paolesse, A. Macagnano, A. Mantini, A. D’Amico, A. Legin, L.
550 Lvova, A. Rudnitskaya, Y. Vlasov, Electronic nose and electronic tongue integration
551 for improved classification of clinical and food samples, *Sensor Actuat. B-Chem.* 64
552 (2000) 15–21.

553 [33] S. Roussel, V. Bellon-Maurel, J.M. Roger, P. Grenier, Fusion of aroma, FT-IR and
554 UV sensor data based on the Bayesian inference. Application to the discrimination of
555 white grape varieties, *Chemometr. Intell. Lab.* 65 (2003) 209–219.

556 [34] S. Buratti, C. Malegori, S. Benedetti, P. Oliveri, G. Giovanelli, E-nose, e-tongue
557 and e-eye for edible olive oil characterization and shelf life assessment: A powerful
558 data fusion approach, *Talanta* 182 (2018) 131–141.

559 [35] H. Men, D. Chen, X. Zhang, J. Liu, K. Ning, Data fusion of electronic nose and
560 electronic tongue for detection of mixed edible-oil, *J. Sens.* 2014 (2014) 1–7.

561 [36] A. Zakaria, A.Y. Shakaff, M.J. Masnan, M.N. Ahmad, A.H. Adom, M.N. Jaafar,
562 S.A. Ghani, A.H. Abdullah, A.H. Aziz, L.M. Kamarudin, A biomimetic sensor for the
563 classification of honeys of different floral origin and the detection of adulteration,
564 *Sensors* 11 (2010) 7799–7822.

565 [37] L. Lu, S. Deng, Z. Zhu, S. Tian, Classification of rice by combining electronic
566 tongue and nose, *Food Anal. Methods* 8 (2015) 1893–1902.

567 [38] F. Han, X. Huang, E. Teye, F. Gu, H. Gu, Nondestructive detection of fish
568 freshness during its preservation by combining electronic nose and electronic tongue
569 techniques in conjunction with chemometric analysis, *Anal. Methods* 6 (2014) 529–
570 536.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 571 [39] Z. Haddi, S. Mabrouk, M. Bougrini, K. Tahri, K. Sghaier, H. Barhoumi, N. El Bari,
572 A. Maaref, N. Jaffrezic-Renault, B. Bouchikhi, E-Nose and e-Tongue combination for
573 improved recognition of fruit juice samples, *Food Chem.* 150 (2014) 246–253.
- 574 [40] M. Righettoni, A. Amann, S.E. Pratsinis, Breath analysis by nanostructured metal
575 oxides as chemo-resistive gas sensors, *Mater. Today* 18(3) (2015) 163–171.
- 576 [41] O. Lawal, W.M. Ahmed, T.M. Nijssen, R. Goodacre, S.J. Fowler, Exhaled breath
577 analysis: a review of ‘breath-taking’ methods for off-line analysis, *Metabolomics*
578 13(10) (2017) 1-16.
- 579 [42] J. Beauchamp, J. Herbig, R. Gutmann, A. Hansel, On the use of Tedlar® bags for
580 breath-gas sampling and analysis, *J. Breath Res.* 2(4), (2008) 046001.
- 581 [43] T. Saidi, T.G. Welearegay, O. Zaim, O.G. León, R. Ionescu, N. El Bari, B.
582 Bouchikhi, Ability of discrimination of breath from smoker and non-smoker controls
583 by using an electronic nose based on WO₃ nanowires and SnO₂ sensors, In *IEEE*
584 *International Symposium on Olfaction and Electronic Nose (ISOEN)* (2017) 1–3.
- 585 [44] T. Saidi, D. Palmowski, S. Babicz-Kiewlicz, T.G. Welearegay, N. El Bari, R.
586 Ionescu, J. Smulko, B. Bouchikhi, Exhaled breath gas sensing using pristine and
587 functionalized WO₃ nanowire sensors enhanced by UV-light irradiation, *Sensor Actuat.*
588 *B-Chem.* 273 (2018) 1719–1729.
- 589 [45] D. Ahmadou, R. Laref, E. Losson, M. Siadat, Reduction of drift impact in gas
590 sensor response to improve quantitative odor analysis, In *IEEE International*
591 *Conference on Industrial Technology (ICIT)* (2017) 928–933.
- 592 [46] O. Zaim, T. Saidi, N. El Bari, B. Bouchikhi, Assessment of "breath print" in
593 patients with chronic kidney disease during dialysis by non-invasive breath screening
594 of exhaled volatile compounds using an electronic nose, In *IEEE International*
595 *Symposium on Olfaction and Electronic Nose (ISOEN)* (2019) 1–4.
- 596 [47] S. Dragonieri, J.T. Annema, R. Schot, M.P. van der Schee, A. Spanevello, P.
597 Carratú, O. Resta, K.F. Rabe, P.J. Sterk, An electronic nose in the discrimination of
598 patients with non-small cell lung cancer and COPD, *Lung cancer* 64 (2009)166–170.
- 599 [48] R. Bro, A.K. Smilde, Principal component analysis, *Anal. Methods* 6 (2014) 2812–
600 2831.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 601 [49] Y. Aït-Sahalia, D. Xiu, Principal component analysis of high-frequency data, *J.*
602 *Am. Stat. Assoc.* 114 (2019) 287–303.
- 603 [50] M. Bougrini, K. Tahri, Z. Haddi, T. Saidi, N. El Bari, B. Bouchikhi, Detection of
604 adulteration in argan oil by using an electronic nose and a voltammetric electronic
605 tongue, *J. Sensors* 2014 (2014) 1–10.
- 606 [51] T. Fawcett, An introduction to ROC analysis, *Pattern Recognit. Lett.* 27(8)
607 (2006) 861-874.
- 608 [52] N. Guenther, M. Schonlau, Support vector machines, *Stata J.* 16(4) (2016) 917-
609 937.
- 610 [53] J.M. Gutiérrez, Z. Haddi, A. Amari, B. Bouchikhi, A. Mimendia, X. Cetó, M. del
611 Valle, Hybrid electronic tongue based on multisensor data fusion for discrimination of
612 beers, *Sensor Actuat. B-Chem.* 177 (2013) 989–996.
- 613 [54] F. Morisco, E. Aprea, V. Lembo, V. Fogliano, P. Vitaglione, G. Mazzone, L.
614 Cappellin, F. Gasperi, S. Masone, G.D. De Palma, R. Marmo, N. Caporaso, F. Biasioli,
615 Rapid “Breath-Print” of liver cirrhosis by proton transfer reaction time-of-flight mass
616 spectrometry. A pilot study, *PLoS One* 8(4) (2013) e59658.
- 617 [55] R.F. Del Río, M.E. O'Hara, A. Holt, P. Pemberton, T. Shah, T. Whitehouse, C.A.
618 Mayhew, Volatile biomarkers in breath associated with liver cirrhosis—comparisons
619 of pre-and post-liver transplant breath samples, *EBioMedicine* 2(9) (2015) 1243-1250.
- 620 [56] U. Srimathi, V. Nagarajan, R. Chandiramouli, Germanane nanosheet as a novel
621 biosensor for liver cirrhosis based on adsorption of biomarker volatiles—a DFT study,
622 *Appl. Surf. Sci.* 475 (2019) 990-998.
- 623 [57] J. Dadamio, S. Van den Velde, W. Laleman, P. Van Hee, W. Coucke, F. Nevens,
624 M. Quirynen, Breath biomarkers of liver cirrhosis, *J. Chromatogr. B* 905 (2012) 17-22.
- 625 [58] A. Mashir, A.R. Tamimi TI, D. Laskowski, K.M. Paschke, D.E. Grove, D.B.
626 Milligan, M. Storer, N. Zein, A. Feldstein, R.A. Dweik, Exhaled breath analysis in
627 patients with liver cirrhosis using soft ion flow tube mass spectrometry (SIFT-MS), In
628 C38. Airway inflammation: from mechanisms to non-invasive biomarkers (2011)
629 A4466.
- 630 [59] R.F. Pfeiffer, Wilson’s disease, *Handb Clin. Neurol.* 100 (2011) pp. 681–709.

- 1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65
- 631 [60] T. Hisaki, T. Furumoto, K. Nozaka, K. Kono, T. Odachi, K. Mizumoto, O.
632 Nishimura, S. Koga, Serum zinc and copper changes after gastrectomy in aged patients
633 with gastric cancer, *Jpn. J. Psychol.* 18 (1988) 158–163.
- 634 [61] G.J. Brewer, F.K. Askari, Wilson's disease: clinical management and therapy, *J.*
635 *Hepatol.* 42 (2005) S13–S21.
- 636 [62] V. Nangliya, A. Sharma, D. Yadav, S. Sunder, S. Nijhawan, S. Mishra, Study of
637 trace elements in liver cirrhosis patients and their role in prognosis of disease, *Biol.*
638 *Trace Elem. Res.* 165 (2015) 35–40.
- 639 [63] A. Agarwal, S. Avarebeel, N.S. Choudhary, M. Goudar, C.J. Tejaswini,
640 Correlation of trace elements in patients of chronic liver disease with respect to Child-
641 Turcotte-Pugh scoring system, *J. Clin. Diagn. Res.* 11 (2017) OC25–OC28.
- 642 [64] A.H. Hunt, R.M. Parr, D.M. Taylor, N.G. Trott, Relation between cirrhosis and
643 trace metal content of liver with special reference to primary biliary cirrhosis and
644 copper, *Br. Med. J.* 2 (1963) 1498–1501.
- 645 [65] European Association for Study of Liver, EASL clinical practice guidelines:
646 Wilson's disease, *J. Hepatol.* 56 (2012) 671–685.
- 647 [66] N.C. Nayak, A.R. Chitale, Indian childhood cirrhosis (ICC) & ICC-like diseases:
648 the changing scenario of facts versus notions, *Indian J. Med. Res.* 137 (2013) 1029–
649 1042.
- 650 [67] R.E. Tanzi, K. Petrukhin, I. Chernov, J.L. Pellequer, W. Wasco, B. Ross, D.M.
651 Romano, E. Parano, L. Pavone, L.M. Brzustowicz, M. Devoto, J. Peppercorn, A.I.
652 Bush, I. Sternlieb, M. Pirastu, J.F. Gusella, O. Evgrafov, G.K. Penchaszadeh, B. Honig,
653 I.S. Edelman, M.B. Soares, I.H. Scheinberg, T.C. Gilliam, The Wilson disease gene is
654 a copper transporting ATPase with homology to the Menkes disease gene, *Nat. Genet.*
655 5 (1993) 344–350.
- 656 [68] G.J. Brewer, V. Yuzbasiyan-Gurkan, Wilson disease, *Medicine* 71 (1992) 139–
657 164.
- 658 [69] L.M. Gaetke, C.K. Chow, Copper toxicity, oxidative stress, and antioxidant
659 nutrients, *Toxicology* 189 (2003) 147–163.

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

660 [70] Y. Yoshida, T. Higashi, K. Nouso, H. Nakatsukasa, S.I. Nakamura, A. Watanabe,
661 T. Tsuji, Effects of zinc deficiency/zinc supplementation on ammonia metabolism in
662 patients with decompensated liver cirrhosis, *Acta Med. Okayama* 55 (2001) 349–356.

663 [71] D. Rahelić, M. Kujundžić, Ž. Romić, K. Brkić, M. Petrovečki, Serum
664 concentration of zinc, copper, manganese, and magnesium in patients with liver
665 cirrhosis, *Collegium Antropol.* 30 (2006) 523–528.

666

667 **Figure captions**

1
2 668 **Fig. 1.** Architecture of the E-nose system used for exhaled breath measurements.
3

4 669 **Fig. 2.** Schematic representation of the VE-tongue dedicated to the analysis of urine
5 samples.
6 670

7
8 671 **Fig. 3.** E-nose responses of: MQ gas sensors when exposed to breath of (a) HC, (b) LCi
9 patient; and interdigitated gas sensors after exposure to VOCs in the breath samples
10 672 from (c) HC, (d) LCi patient.
11 673

12
13 674 **Fig. 4.** Responses of the five-electrode arrays of VE-tongue and insights without Cu
14 electrode towards urine samples from: (a) HC, (b) patient with LCi.
15 675

16
17 676 **Fig. 5.** Radar plots of E-nose gas sensors responses towards exhaled breath from HC
18 and patient with LCi, expressed by area as a feature.
19 677

20
21 678 **Fig. 6.** Radar plots of the responses of the VE-tongue electrode array exposed to the
22 two different sets of urine samples, expressed by Pt_{ox} as a feature.
23 679

24
25 680 **Fig. 7.** Unsupervised PCA plot showing data points for: (a) breath samples relating to
26 the two health states with data collected from the E-nose, (b) urine samples relating to
27 681 the two health states with data collected from the VE-tongue.
28 682

29
30 683 **Fig. 8.** Supervised DFA plot displaying data points for: (a) breath samples relating to
31 the two health states with data collected from the E-nose, (b) urine samples relating to
32 684 the two health states with data collected from the VE-tongue.
33 685

34
35 686 **Fig. 9.** ROC curve displaying data points for: (a) breath samples relating to the two
36 health states with data collected from the E-nose, (b) urine samples relating to the two
37 687 health states with data collected from the VE-tongue.
38 688


39
40 689 **Fig. 10.** Unsupervised PCA plot showing data fusion of E-nose and VE-tongue systems.
41

42
43 690 **Fig. 11.** Supervised DFA plot showing data fusion of E-nose and VE-tongue systems.
44

45
46 691 **Fig. 12.** ROC curve showing data fusion of E-nose and VE-tongue systems.
47

48
49 692
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


693 Fig. 1.



694

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


695 **Fig. 2.**



696

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

697 **Fig. 3.**




698

699

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


700 **Fig. 4.**



701

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

702 **Fig. 5.**




703

704


1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

705 **Fig. 6.**



1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


706 Fig. 7.



707
708

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


709 **Fig. 8.**



710
711

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65


712 **Fig. 9.**



713

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

714 **Fig. 10.**




715

716

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

717 **Fig. 11.**




718

719

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

720 **Fig. 12.**



721

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

722 **Table 1**

723 General characteristics of all studied volunteers.

Volunteers					
Groups	Number	Age range (years) Age \pm SD*	Male, number (%)	Smoking habit ⁺	Medication
Liver cirrhosis (LCi)	22	24-79 46 \pm 15	10 (45%)	1 S, 3 Ex.S, 18 NS	- Ciprofloxacin - Aldactone - Autocardyl - Tefovin
Healthy controls (HC)	32	21-64 37 \pm 17	22 (69%)	8 S, 24 NS	————

724 * **SD:** Standard Deviation.

725 + **Smoking habit:** S: Smoker, Ex.S: Ex-Smoker, NS: Non-Smoker.

726

727 **Table 2**

728 Commercial gas sensors used in the e-nose system.

Gas Sensors	Target Compounds
MQ-2	Propane, Hydrogen, Methane
MQ-3	Alcohol
MQ-135	Benzene, Ammonia, Carbon dioxide and Nitric oxide
MQ-137	Ammonia
MQ-138	Toluene, Acetone, Methanol, Ethanol and Formaldehyde

729

730

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

731 **Table 3**

732 SVMs results for the classification of 60 breath samples regarding their health states
733 by using the E-nose system with a success rate of 98.33%.

Actual	Predicted	
	LCi patients	HC
LCi patients	29	1
HC	0	30

734

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

735 **Table 4**

736 SVMs results for the classification of 120 urine samples regarding their health states
737 by using the VE-tongue system with a success rate of 97.50%.

Actual	Predicted	
	LCi patients	HC
LCi patients	57	3
HC	0	60

738

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65

739 **Table 5**

740 SVMs results for data fusion of E-nose and VE-tongue systems with a success rate of
741 100%.

Actual	Predicted	
	LCi patients	HC
LCi patients	30	0
HC	0	30

742

1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
61
62
63
64
65